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Abdominal aortic aneurysm (AAA) is focal ballooning and dilation of abdominal 
aorta. AAAs are the 13th primary cause of death in the US, taking the lives of 
approximately 15,000 Americans each year 1.  The best prevention of AAA is early 
detection when the AAA is smaller than 3 cm. The only current treatment option for well-
developed AAA is surgical repair of the aneurysmal vessel. Since the enactment of the 
Screening Abdominal Aortic Aneurysms Very Efficiently Act (SAAVE) act, patients 
with Medicare are covered for one-time ultrasound imaging for aneurysm, which allows 
smaller scale AAAs to be discovered. Unfortunately, after this initial detection there is no 
currently known treatment to slow the growth of these aneurysms. Monitoring can be 
continued through the use of ultrasound imaging or plain film radiography, which shows 
calcification related to the AAA, but there is no effective way to show a full picture of 
focal wall weakening 2.  When the AAA has a diameter greater than 5.5 cm, elective 
surgery is typically performed as the risk of surgery is less than the risk of a ruptured 
AAA. 
Excessive activity of metalloproteinases (MMPs) has been associated with aortic 
elastin damage and degeneratio3.  Also AAA is often associated with calcification, which 
increases the risk of AAA rupture 4.  Based on this knowledge, we hypothesized that 
combined treatment MMP inhibitors locally to stop the degradation of elastin, and 
pentagalloyl glucose (PGG) to regenerate lost elastin can be an effective treatment option 
for early to middle stage aneurysms in order to prevent disease progression. Furthermore, 




first with ethylene diamime tetraacetic acid (EDTA), a well-known metal ion chelator 
and then degraded elastin can be regenerated with PGG.   The overall goal of this study 
was to develop a minimally invasive, non-toxic, targeted vascular drug delivery system 
that both prevents elastin degradation and aids elastin regeneration, thereby acting as a 
multi-functional treatment option for elasto-degenerative vascular diseases including 
AAAs. In order to achieve this goal, we used nanoparticles (NPs) developed in our 
laboratory to target degraded elastin by conjugating elastin antibody that specifically 
recognizes only degraded elastin. First, using calcium chloride-induced AAA rat model, 
we show targeted delivery of such nanoparticles loaded MMP inhibitor (BB-94) lead to 
suppression of MMP activity in abdominal aortic aneurysms and prevented aneurysmal 
expansion. Next, we demonstrated that nanoparticles can be loaded with PGG. In AAA 
model in rats, we show PGG can be delivered at the site of AAA by targeted NPs. Such 
PGG delivery inhibited elastin degradation and lead to suppression of AAA.  Finally, we 
tested whether moderate size calcified aneurysms could be reversed by dual therapy. We 
created moderate size AAA in rats by calcium chloride injury, and then first delivered 
EDTA loaded NPs systemically to remove calcification followed by delivery of PGG 
loaded NPs. Only dual therapy showed reversal of calcification in the aorta as well as 
reversal of AAA and regeneration of elastic lamina. NPs with EDTA alone or blank NPs 
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Abdominal aortic aneurysm (AAA) is the dilation or ballooning of part of the 
aorta located in the abdominal region.  There are typically no symptoms associated with 
AAAs until it reaches an advance stage, and the bursting of the AAA is often fatal.  
AAAs less than 5.5 cm wide are considered to have a low chance of rupturing and are 
designated as small AAAs.  Any abdominal aortic aneurysm larger than 5.5 cm wide5 is 
considered a large AAA and often an operation to repair is advised if the risk of rupture is 
greater than that of surgery6.  Males 65-years-old and older and those who have smoked 
100 cigarettes or more are offered a routine ultrasound screening for AAA through 
Medicare.  Routine screening is now allowing diagnosis of early stage aneurysms.  
Unfortunately, there are no known pharmacological approaches for treating small AAA 
in humans or retarding AAA growth7.  However, there are multiple drugs that have been 
found to prevent AAA formation and progression in small animal studies.  These findings 
have generated a large amount of interest to treat patients with small aneurysms, and have 
led to some initial investigative studies.  In one study, 121 patients who received a Beta 
blocker had a significantly lower mean growth rate than those who did not (0.36 versus 
0.68 cm per year)8,9.  Another class of successful drugs, statins, are suggested for AAA 
patients to reduce atherosclerosis development10.  Additionally, there have been at least 
14 independent in-vivo studies on doxycycline that have shown it limits aneurysm 
progression.  Systemic delivery of doxycycline is known to decrease inflammatory 




rates10,11.  We believe one reason behind the failure of these drugs is that systemic 
administration at approved dosage levels does not provide the necessary therapeutic 
levels at the site of AAA.  If we were able to deliver the drugs locally, it would improve 
the therapeutic efficacy and prevent systemic side effects. 
Furthermore, inhibition of ECM degrading enzymes can halt the progression of 
the disease but it cannot reverse already degraded ECM.  One of the hallmarks of 
aneurysm is the degradation of elastic lamina in the medial region of the aorta.  Elastic 
fibers are created during early development and are made up of a cross-linked elastin core 
(amorphous elastin) residing in a network of microfibril associated glycoproteins 
(MAGPs), latent TGF-beta binding protein (LTBP) and fibulins12.  
Elastic fibers can undergo degeneration during inflammatory diseases13.  
Atherosclerotic disease or excessive smoking can cause chronic inflammation in arteries 
that can lead to elastic fiber degeneration and formation of aortic aneurysms.  Once 
degraded, it is rarely remodels in elderly patients.  Little work has been done on the 
regeneration of elastin for AAA treatment.  This is important because other ECM 
components such as collagen and glycosaminoglycans are remodeled during disease but 
older diseased cells are unable to repair and remodel degraded elastin14. 
During this dissertation research, we have explored the use of targeted 
nanoparticles that can deliver synthetic MMP inhibitors to the aneurysmal aorta to reduce 
MMP activities, protect elastin from proteolytic damage, and improve the integrity of the 
abdominal aorta.  We further investigated whether nanoparticle based targeted treatment 




polyphenols) while reducing inflammation and calcification (by delivery of the chelating 
agent EDTA) in the artery.  Overall, our plan was to find treatments that were effective in 
halting and reversing aneurysms and healing AAAs.  
We were successful in formulating polymeric nanoparticles (NPs) based on either 
poly-l-lactic acid (PLA) or bovine serum albumin (BSA) that had been decorated with 
elastin antibodies to be able to recognize and attach to damaged aortic elastin.  Such NPs 
were successfully loaded with synthetic MMP inhibitor, polyphenolic compound PGG, 
and EDTA.  
This dissertation has been formatted in the following sections: 
 
1. In Chapter II, we present a comprehensive overview of the cardiovascular 
system, its structure, function, biomechanics, elastic moduli, elastin in aorta, 
vascular disease, specially AAA, and treatment recommendations as well as 
pharmacological treatment options available today. 
 
2. In Chapter III, we provide the rational of the research and specific aims.   
 
3. In Chapter IV, we discuss the prevention of abdominal aortic aneurysm 
progression by targeted inhibition of matrix metalloproteinase activity with 
Batimastat-loaded nanoparticles.  
 
4. In Chapter V, we present targeted therapy with nanoparticle loaded with 
pentagalloyl glucose (PGG) to protect vascular elastic lamina from MMP-
mediated degradation and show that it prevents progression of abdominal 
aortic aneurysm (AAA) in calcium chloride injury mediated AAA 
development in rats. 
 
5. In Chapter VI, we present dual therapy using EDTA loaded nanoparticles 
along with PGG loaded nanoparticles to reverse abdominal aortic aneurysm in 
an advance stage in a calcium chloride injury mediated AAA development in 
rats. 
 
6. Chapter VII provides conclusion of the present research and future directions 
















The Cardiovascular System 
 
The cardiovascular system functions to carry blood and lymph throughout the 
body15.  It is divided into four sub units:  the heart, macrocirculation, microcirculation, 
and lymph vascular systems16.  Blood vessels vary with size and function, but each has 
three layers, or tunics, which means “coat” in Latin.  The deepest layer, the tunica intima, 
makes up the typically simple squamous endothelial lining of the vessel.  The tunica 
media, the middle layer, consists of smooth muscle and some connective tissue fibers, 
and the outermost layer, the tunica externa, is primarily connective tissue with 
fibroblasts17 (See Figure 1). 
Arteries carry blood from the heart to various organs and can be categorized by 
their size.  Those with a diameter below 0.5 mm are known as arterioles.  Muscular or 
distributive arteries are medium sized, and elastic arteries are the largest.  Capillaries, the 
smallest blood vessels, are responsible for gas transfer and are 7–9 µm in diameter18.  
Veins bring blood to the heart from various organs.  They have three categories based on 
the size as well.  Venules are the smallest followed by medium and large veins.  
Compared to veins, arteries have thicker walls as they need to withstand more pressure19. 
 
Biomechanics of Aorta 
 
The rupture of aneurysmal vessel wall counts as a mechanical failure, so the 
biomechanics of AAA has been studied extensively21.  The mechanical properties of 






Figure 1.  Sections of blood vessels composed of three main layers20. 
 
 
mechanical properties is to predict AAA rupture22.  Blood vessels can attribute most of 
their mechanical properties to their makeup of collagen and elastin fibers, ground 
substances, and smooth muscle cells.  Alan Burton and his colleagues were the first group 
to make the connection between the microstructure of the vessel and its resulting 
macroscopic mechanical properties23.  Using the differential digestion of elastin and 
collagen in the arteries, they were able to measure the corresponding variations in the 
mechanical properties of the wall.  Their finding resulted in the formation of a theoretical 





Young's modulus or elastic modulus is determined as the slope of the linear 
portion of a uniaxial stress strain curve25.  Elastic modulus of AAA could provide 
parameters for analysis of AAA wall stress distribution and predicting rupture of AAA22. 
 
The Blood Pressure and Its Effect on the Aortic Wall 
 
When studying the arterial pressure in the aorta, the aorta can be compared to an 
inflated tube-like construction26.  This pressure can be translated directly to tension based 
mechanical stress on the wall, with the circumferential and axial stresses acting as the 
major stresses (See Figure 2).  During inflation, the wall undergoes an isochoric 
deformation, where tissue volume is constant, leading to weakening of the wall in the 
circumferential and axial directions.  
As a rule, as the aortic diameter increases, the wall becomes proportionally 
thicker.  Medial lamellar units (MLU) increase with wall thickness.  Thus, each MLU 
carries a tension of about 2 ± 0.4 N/m, and it’s been shown that substantial decrease in 
wall thickness and the number of MLU’s happens during aneurysmal changes27,28.  
Stiffness is the slope of the load-deformation curve29.  Aorta stiffness increases with 
strain which means that at hypertensive loading the aorta will be stiffer than during 
normal arterial pressure27,30.  When stiffness of aneurysmal and healthy vessel was 
compared, result showed that aneurysmal section were stiffer than the healthy section 
with less collagen and elastin content21.  
Stiffness of the artery depends on its intrinsic elasticity.  Pulse wave velocity 
(PWV) is a direct measure of large arterial stiffness31.  Circumferential cyclic Green-






Figure 2.  Different types of stress in aortic wall. 
 
 
cyclic Green-Lagrange strain use ultrasound and offer a noninvasive assessment of 
stiffness along an arterial section33. 
 
Structure of Aortic Elastin 
 
Making up roughly 50% of the arterial ECM, elastin is the most prevalent 
structural protein of the arteries34.  Elastin is made up of elastic fibers that have two 
major components, one amorphous and one fibrillar.  The extensively cross-linked elastin 
of the amorphous component comprises 90% of the fiber.  The fibrillar component, is a 




Amorphous elastin forms from monomers of soluble tropoelastin.  Tropoelastin arises 
during prenatal development when elastogenic cells including smooth muscle cells 
(SMCs), endothelial cell, fibroblasts and chondroblasts express the elastin gene36.  
Humans only contain one tropoelastin gene, ELN.  As we age, ELN expression decreases 
dramatically as elastin production decreases.  In middle-aged people, elastin production is 
almost non-existent, so we must rely on the elastin deposition that occurs in the womb 
and early in life37.  In order to make elastin, tropoelastin molecules must interact and then 
crosslink, forming insoluble elastin.  Fibrillin-1 largely makes up microfibrils in ECM 
that likely anchor the forming elastic fibers38.  Lysyl oxidases are a group of five 
enzymes including LOX, and LOXL 1-4, which cross-link tropoelastin and aid the 
process39.  
Initially, tropoelastin is expressed then secreted into the ECM.  In a closer look, 
the mature tropoelastin begins to accumulate on the surface on the cell to create 1 micron 
spherules.  This accumulation of tropoelastin aids coacervation of tropoelastin molecules.  
Eventually, the tropoelastin is oxidized by the lysyl oxidase enzymes and then participate 
in aldol condensation and Schiff base reactions to crosslink elastic fibers.  The 
microfibrils that exist in the ECM are transported to where the new elastin is being 
formed, by members of the fibulin protein family.  The elastin produced as the final 
product is very stable and able to give human tissue the ability to stretch and recoil40 (See 
Figure 3).  
          Elastin binding protein (EBP), made of a 67-kDa peripheral subunit attached to two 






Figure 3.  Elastin assembly40. 
 
 
tropoelastin molecules to fibre formation sites on the surface of cells. Initially, 
tropoelastin binds to an EBP complex that is intact. The 67-kDa subunit loses its affinity 
for tropoelastin and the membrane bound protein when a sugar moiety binds to the EBP. 
The loss of affinity lease to tropoelastin being released onto growing elastic fibers 35. 
Smooth muscles cells (SMCs) and fetal lung fibroblasts go through a different 
process of binding to tropoelastin.  SMCs, much like chondrocytes, use heparin sulfate 
chains through proteoglycans on the cells surface to bind to the tropoelastin.  In the fetal 










Vascular disease may result from any circulatory system disorder.  It includes 
Peripheral Artery Disease, Aneurysms, Renal (Kidney) Artery Disease, Buerger's 
Disease, Peripheral Venous Disease and etc.42  Vascular disease is a subgroup of 
cardiovascular disease (CVD).  CVD, often brought on by risk factors such as high blood 
pressure, high LDL cholesterol, and smoking, is the primary cause of death in the United 
States.  At least one of these risk factors is present in nearly half (49%) of Americans43.  
Other lifestyle choices and medical conditions, namely diabetes, excessive weight, poor 
diet, lack of physical activity44, and overuse of alcohol, can increase the risk of heart 
disease25.  The prevalence of heart disease across the United States is shown in Figure 4. 
 
Abdominal Aortic Aneurysm (AAA) 
 
Weakening and resulting focal bulging of the abdominal aorta are known as 
abdominal aortic aneurysms (AAAs)46. The AAA disease is diagnosed when the 
minimum diameter between the anterior and posterior walls of the aorta is 3.0 cm47.  
Much like other cardiovascular diseases, AAAs occur more frequently in males and often 
dependent of risk factors including advanced age, tobacco use, and family history.  
American College of Cardiology/American Heart Association (ACC/AHA) guidelines 
list the occurrence of AAAs between 2.9 and 4.9 cm in diameter as 1.3% for 45-54 year 
old men and 12.5% for 75-84 year old men48.  While there is limited data on the 







Figure 4.  Heart disease rate of death across the US45. 
 
 
aneurysmal aorta is mechanically weaker than healthy aorta, both longitudinally and 
circumferentially, and the resulting weakness is the main cause of rupture49,50.  
 
Risk of Rupture 
 
Randomized studies comparing immediate repair and monitoring of small AAAs 
largely comprise the general theory of AAA progression and risk of rupture.  The results 
show that the yearly risk of rupture is less than or equal to 1% for those AAAs with a 
diameter below 5.5cm, but it increases with the size of the aneurysm.  For individuals that 




one lager than 8 cm.  The risk of rupture also increases for smokers, women, people with 




Early stage AAA has no major symptoms thus it  makes the threat of rupture that 
much more serious 52.  A treatment plan has to take into consideration both the disease 
progression, risk of rupture, and patient life expectation as well as the mortality potential 
that comes with attempted prophylactic surgery.  The guidelines currently set in place by 
the ACC/AHA state patients with AAAs between 4.0 and 5.4 cm are to be checked by 
ultrasound or CT scans, while patients with AAAs larger than 5.5 cm should have the risk 
of rupture eliminated through surgery53.  Furthermore, asymptomatic male patients with 
an AAA less than 5.0 cm and asymptomatic female patients with an AAA below 4.5 cm 
should not undergo interventional repair techniques, but repair can be beneficial on an 
AAA between 5.0-5.4 cm6.  
 
EVAR vs. Open Surgery  
 
The most common and effective methods for repairing abdominal aortic 
aneurysms are abdominal endovascular aneurysm repair (EVAR) and the more traditional 
open surgery (shown in Figure 5).  EVAR involves a small incision in the groin that 
allows the placement of a stent graft in the aneurysm, whereas open surgery involves a 
synthetic graft being placed in the walls of the aneurysm54.  Comparing EVAR with open 







Figure 5.  Open Repair vs EVAR57. 
 
 
1.6 % for EVAR and 4.7 % for open repair of AAA.  Given the 30 days post-surgery 
outcome, this may help both surgeon and patient in choosing treatment options6,55,56.  
 
Mortality of Ruptured AAA (rAAA) 
 
In a study in a specific geographical area, the mortality rate for rAAAs was 
assessed and found to be 6.3/100,000 inhabitants for the annual incidence.  In one the 
clinical studies58, about 37% or 82 out of 221 patients did not make it to the hospital 
before they died.  Of those patients who were admitted, 79.8% went through immediate 
surgery.  For the entire hospital, the mortality rate was 63.3%, while the cumulative 





Animal Models for AAA 
 
In any animal model, the goal is to model human disease pathology as closely as 
possible, in order to effectively evaluate the mechanisms that occur in humans.  For 
aneurysms, currently no exact model exists, and so conclusions are drawn based on 
assumptions the biochemical and cellular mechanisms that occur in the animals are 
comparable to those in humans.  Of course, each different experimental model of AAA 
has its own pros and cons.  Most techniques of physical, chemical, and genetic 
manipulations on healthy vasculature have been used on almost every typically tested 
species.  Table 1 shows the advantages and disadvantages of animal species for AAA 
research. 
 
Surgically Induced Aneurysms 
 
Blunt trauma and/or crush injuries to the arterial wall are two of the most common 
ways to create the mechanical weakness necessary to induce an experimental AAA60.  
Artificially reducing the arterial diameter in certain locations can create the turbulence 
and shear stress that result in enough dilation to cause an aneurysm.  An aneurysm 
phenotype can also be created through the implantation of arterial tissues from a foreign 
species61.  The resulting immune rejection requires about four weeks to progress until it is 
deemed to effectively mirror an aneurysm.  Each of these techniques of creating 
aneurysms achieves the desired purpose at the cellular level which trauma to the arterial 
wall and a strong immune response.  This is characterized microscopically by a 
congregation of T-cells, B cells, and macrophages and a loss of both extracellular and 




Table 1.  Advantages and disadvantages of animal species for AAA research59. 
 
Animal Species advantages Species disadvantages 
Mouse  Fairly low costs 
 Well-characterized genome 
facilitates genetic manipulation 
 Very small aorta 
 Genetically manipulated models 
can be expensive 
Rat  Fairly low costs 
 Larger size of vessels compared to 
mice 
 Genetic manipulation is difficult 
Swine  Similar arterial morphology to 
humans 
 Variable aneurysm formation 
following elastase perfusion 
Rabbit  Relatively low costs  Poor public perception of studies 
based in rabbit species 
Canine  Large peripheral arteries 
 Able to survive prolonged 
anesthesia 
 High cost 
 Poor public perception of studies 
based in canine species 
Sheep  Large arteries  High cost  
Turkey  Form spontaneous aneurysms  N/A 
 
Chemically Induced Aneurysms 
 
According to initial clinical research, elastolysis of the aortic media was a major 
player in pathophysiological beginning of a human AAA, and elastase was at the center 
of the destruction occurring the elastic tissue of the aortic wall62.  Atherosclerosis, the 
hardening of the elastic wall, also showed similar patterns of calcification and 
fragmentation of elastic tissue that appeared in AAAs63.  Therefore, the administration of 
chemical solutions of elastase and calcium chloride to the infrarenal aorta is the most well 




In the 1960s, transient intraluminal perfusion with pancreatic elastase into the 
abdominal aorta was first documented as a technique to induce experimental AAAs64.  




that have undergone elastase infusion has found a number of similarities.  Notably, this 
analysis has demonstrated that the medial elastic tissue destruction is increased due to 
inflammatory response created by aortic dilation, while the rate of aneurysm formation 
post-aortic elastase treatment is not correlated  59. 
 
Calcium Chloride-Induced Aneurysms 
 
Calcification is closely associated with aneurysms, and heavy calcification is seen 
in about 80% of human AAAs65.  Knowing the commonality of calcification in AAAs, in 
1988 Gertz et. al.,66 conducted a pioneering study on male New Zealand rabbits, 
determining that the application of CaCl2 to the adventitia of the carotid artery resulted in 
the formation of an aneurysm.  In the study, the researchers immersed the entire 
adventitial surface of the right common carotid artery in a 0.5M CaCl2 solution for 15 
min.  After three weeks, the luminal diameter of the treated arterial segment had 
increased by an average of 61% as compared to the opposite carotid artery which was 
treated with sodium chloride (NaCl) instead.  A histological examination using scanning 
electron microscopy (SEM) revealed endothelial cell fragmentation where the calcium 
chloride was administered, as well as, elastin calcification, loss of vascular smooth 
muscle cells, and a strong immune response characterized by the presence of neutrophils, 
monocytes, foreign body giant cells, and lymphocytes.  This study was the first recorded 
model of a human aneurysm67.  Other studies have tried to recreate the model with 
variable conditions including Freestone et al.  They used a 0.25 M v solution instead, but 
even 12 weeks after surgery there was no AAA formation.  A second attempt was made 




AAA formation was seen in just three weeks68.  This model was successful in both 
rabbits and rodents.  Another technique applying a 13.6 mEq/10 mL CaCl2 solution 
applied to abdominal aorta of C57BL/6 mice resulted in AAA formation, degradation of 
elastin, reduction of VSMC, and lymphocyte and macrophage infiltration69.  CaCl2 has 
been documented to increase endothelial permeability and induce VSMC apoptosis when 
applied to vasculature, as well as causing the infiltration of the adventitia and media of 
the aorta by inflammatory cells70,71.  These documented animal models have been shown 
to closely mirror human AAAs in terms of their pathology due to aortic calcification, 
increased presence of inflammatory cells, degradation of elastin, neovascularization, 
oxidative stress, and VSMC apoptosis.  The main issue with the CaCl2 AAA model is 
that it does not result in intraluminal thrombus and rupture as is seen in human AAAs67. 
 
Genetically Manipulated Models of AAA 
 
Sophisticated techniques of altering genes have allowed researchers to more 
specifically dissect the mechanisms that lead to pathogenic phenotypes, thus allowing 
researchers to obtain a better idea of therapeutic targets.  Genetically modified organisms 
(GMOs) are growing in number and complexity as techniques are being improved and 
expanded, allowing medical researchers to apply their knowledge of GMOs to their 
research.  An example of this is the process of creating “gene knockout mice”, which are 
genetically deficient due to the targeted disruption of one or more alleles.  These mice are 
gaining an integral role in research regarding the pathophysiology of vascular diseases.  




increase.  Below the specific relevance of gene knockout mice to human AAA research 
will be discussed.59. 
 
Angiotensin II and Hyperlipidemic Mice 
 
Aortic aneurysms in mice have been created by infusing octapeptide angiotensin-
II (ang-II) subcutaneously.  When the ang-II is delivered to hyperlipidemic strains of 
mice, typically deficient in apolipoprotein E (Apo E−/−) or in low-density lipoprotein 
receptor (LDLR−/−), the mice’s pre-existing disposition to aneurysms is inflamed, 
resulting in small aneurysm formation.  While this model successfully creates 
atherosclerotic plaque similar to that seen in human AAAs, the AAAs in mice occur 
sporadically and occasionally supra-renally, which does not occur in humans72-74. 
 
Pharmacological Management of Small Abdominal Aneurysm  
 
Even though AAA has high rates of mortality and morbidity, ranking in the top 
fifteen of most recurrent causes of death in men over 55 in western societies75, little is 
known about the cause and development of AAA.  Non-invasive observational imaging 
such as ultrasound, computerized tomography(CT), scans, or magnetic resonance 
imaging (MRI), combined with angiography76 is used to make a diagnosis.  Images 
revealing an abdominal aorta with a diameter of 3 cm and above typically indicate the 
formation of an aneurysm.  Currently, surgical techniques including conventional and 
endovascular repair on AAAs are used in high rupture risk patients, defined as those with 
an AAA with a diameter of 5.5 cm or greater, and have been deemed effective treatment 




those with smaller aneurysms, less than 5.5 cm, without an effective treatment.  They are 
generally recommended to wait until the aneurysm grows to the size where an operation 
is deemed worth the risk, anxiously waiting as their condition worsens77.  
While what causes the degeneration of aneurysms may not be not known, it is 
established that AAAs are connected with chronic transmural inflammation78 and the 
breakdown and elimination of essential proteins in the connective tissue of the outer 
aortic wall.  Simply, three steps can summarize the progression of AAAs (See Figure 6).  
First, the vascular wall begins to increase production of substances that trigger 
inflammation, although these specific substances are not well known.  Next, infiltrating 
cells release molecular mediators.  Finally comes the release of metalloproteinases and 
their respective inhibitors, controlled by the inflammatory agents and infiltrated cells 
from the earlier steps.  Activated macrophages are responsible for producing of the 
MMPs, specifically of MMP-9 and MMP-2, that are not counter-balanced by the activity 
of their inhibitors (TIMPs)79.  This imbalance is primarily responsible for degradation of 
collagen and elastin, which are integral part of the ECM.  The destruction of the collagen 
and elastin interferes with the ordered lamellar structure in the tunica media of the aorta, 
leading to the formation of the aneurysm80.  When examining human AAA tissue, an 
excessive presence of inflammatory infiltrates containing both lymphocytes and 






Figure 6.  Flow chart showing progression of molecular mediators during formation of 
abdominal aortic aneurysm76. 
 
 
above theory.  Additionally, a correlation between increasing aneurysm diameter and 
higher density of inflammatory cells in the adventitia has been confirmed81. 
The main goal of current research related to AAAs is to find new treatments that prevent 
the expansion of small aneurysms.  At this time, majority of research in this field is 
concentrated on the third step of formation, trying to either decrease the presence of 






Figure 7.  Preventing MMPs activation as a therapy for AAA. 
 
 
doxycyclines, statins, and synthetic MMP inhibitors have shown potential and are 
undergoing testing.  
 




Tetracyclines were discovered in 1948, as a product of the fermentation of 
Streptomyces aureofaciens82.  Based on their origin, they can be classified into one of 
three different groups, either natural products, semi-synthetic compounds, or chemically 
modified tetracyclines83.  Besides being powerful antibiotics, tetracyclines are known to 
inhibit MMPs and aid in T-lymphocyte transmigration by preventing chemotaxis and the 
mass movement of neutrophils.  Additionally, doxycycline specifically targets endothelial 




decreasing both protein and mRNA levels which in turn alters endothelial migration that 




Statins, which are widely used to lower lipid levels, are specifically 
hydroxymethylglutamyl-coenzyme A (HMG-CoA) reductase  inhibitors84.  Statins have 
also been demonstrated to prevent atherosclerosis progression for reasons unrelated to the 
benefits of lower lipid levels, which are known as “pleiotropic statins effects”.  
Specifically, these pleiotropic statins’ effects may include anti-oxidant effects, anti-
inflammatory effects, and reduction of MMP secretion, which have been shown to 
prevent AAA development in a number of studies85.  For example, three separate types of 
statins, pravastatin, simvastatin, and fluvastatin, have been shown to reduce MMP-9 
production in the AAA and its infiltrated cells86.  Further studies on simvastatin have 
shown it to increase TIMP-1 production although it had no effect on the infiltration of 
inflammatory cells into the AAA87.  Atorvastatin, on the other hand was effective in 
suppressing the recruitment of macrophages directly by MMP-12 inhibition, primarily by 
inhibition of the expression of intercellular adhesion molecule-1 within the vascular wall88.  
Despite these positive results, it should be noted that in some human studies there has 
been no noticeable effects on AAA growth by statins.  Furthermore, no association has 
been found between AAA expansion and a statin-based treatment or serum low-density 
lipoprotein (LDL) concentration.  However, these studies are contrasted by other studies 
in which statins did show an ability to reduce or delay AAA expansion in humans.  One 




in a significant survival benefit in patients with a ruptured AAA.  A separate 
observational study of 130 patients that were monitored for 2 years found that there was 
no expansion of aneurysms in the 75 patients that were administered statins90.  A few 
other studies have also show similar benefits for statins, suggesting that there is a 
decrease in aneurysm expansion rate for patients being treated with statins as opposed to 
those who were not91.  Further investigation about statins has revealed important 
information about the molecular pathways through which statins can inhibit the growth of 
AAAs.  Pravastatin was particularly ineffective in this setting; however, it was effective 
in increasing TIMP-1 content.  This shows that increased TIMP-1 expression is unrelated 
to HMG-CoA inhibition, and its benefits are not limited by MMP-9 inhibition92.  Another 
suspicion of the benefits of pravastatin is that it may be involved in preventing apoptosis, 
often elevated in AAAs, because pravastatin has been shown to increase the expression of 
Bax, a proto-oncogene known to induce apoptosis, but not the expression of Bcl-2, a 
proto-oncogene that reduces apoptosis.  When analyzing the ratio of Bax/Bcl-2, an 
important index of apoptosis, it was unchanged, rendering any conclusions about 
pravastatin affecting apoptosis in AAAs invalid93.  Based on this, it can be hypothesized 
that TIMP-1 influences other factors that prevent AAA progression, such as growth 
factor-like activity, anti-inflammatory activity, and aortic smooth muscle cell 
proliferation.  Although the specific molecular mechanism used by statins has yet to be 
determined, statins may still function to control AAA growth.  Studies evidencing the 




diminishing MMP expression, and enhancing TIMP synthesis show potential for their 
ability to prevent AAA growth76. 
 
Synthetic Inhibitors of MMPs 
 
MMPs known formally as matrix metalloproteinases are a group of 
endopeptidases that contain zinc and are calcium dependent94.  They function to remodel 
tissue, by degrading parts of the ECM such as elastins, collagens, proteoglycans, and 
matrix glycoproteins.  Hormones, growth factors, and cytokines are able to regulate 
MMPs95.  Most commonly, MMPs are produced via excretion from a number of pro-
inflammatory cells like macrophages, neutrophils, and lymphocytes and connective 
tissues cells such as fibroblasts, osteoblasts, and endothelial cells73.  The zymogens that 
these enzymes are expressed as are processed further to reach active form by other 
proteolytic enzymes including plasmin, furin, serine proteases, and others96.  Currently, 
there are 26 known human MMPs (See Figure 8) that can be categorized into 4 groups:  
collagenases, gelatinases, stromelysins, and matrilysins97.  There is a further subclass 
known as membrane-type MMPs (MT-MMPs), which either have an intracellular and 
transmembrane domain, a membrane linker domain, or are membrane associated.  They 
also have an extra transmembrane domain to anchor them to the surface of the cell.  The 
remainder of the MMPs has a distinct domain, either a hinge region, a catalytic domain, 
an N-terminal domain, or a C-terminal hemopexin-like domain.  The membrane is 
























Mechanism of Action 
 
The majority of matrix metalloproteinase inhibitors act as chelating agents, 
meaning they block activity by binding to the zinc at the active center of the enzyme99. 
Synthetic MMP inhibitors have been created primarily through the use of a 
peptide sequence that the targeted protease can recognize.  This peptide sequence has also 
had a number of chemical functionalities attached that allow it to react with the zinc ion 
at the active site inhibiting the enzyme.  There are a few key requirements for a molecule 
to function properly as an MMP inhibitor, including, an attached functional group that 
can chelate the zinc (II) ion of the active site, a functional group with a hydrogen bond 
that can bind with the backbone of the enzyme, and at least one side chain capable of van 
der Waals interactions on the subsites of the enzyme100.  Functional groups capable of 
chelating the zinc ion would include hydroxamate (CONH–O), carboxylate (COO), and 
thiolate (S), among others.  Using methods including structure-based design and 
combinatorial chemistry, a number of different structural classes of MMP inhibitors have 
been discovered.  Current MMP inhibitors in use include marimastat, trocaid, CGS-
27023A, prinomastat, AG3340, BAY 12-9566, Ro 32-355594. 
 
Pioneering Hydroxamate Structures 
 
Hydroxamate-based MMP inhibitors are much like their name, inhibitors that use 
a hydroxamate (=CONHOH) group to bind to the zinc101.  Two of these inhibitors, 




Batimastat (Figure 9), is a broad-spectrum MMP inhibitor and more commonly referred 
as BB-94, has been effective in inhibiting inflammatory responses in rats, decreasing the 
aneurysm expansion103.   
BB-94 has been shown to decrease inflammatory response to aneurysms, in 
addition to acting as a metalloproteinase inhibitor103; unfortunately, due to a lack of 
bioavailability it is limited for long term use.  A second generation of these, Marimastat, 
is used orally in cancer treatment but 30% of patients had musculoskeletal side effects.  
Most studies on Marimastat have examined intimal hyperplasia and aneurysms in human 
ex vivo tissue104.  While initially promising, these drugs have shown few therapeutic 
benefits in humans and have thus been overlooked for their potential to treat other 
conditions.  
Typically, hydroxamate-based MMP inhibitors tested in in vitro tumors cells have 
shown exceptional anticancer behavior however, when tested clinically, they did not 
perform adequately.  This could be explained at least in part because these broad-
spectrum inhibitors work on other metalloproteinases unrelated to pathology like 
disintegrin and metalloproteinase (ADAMs) proteases.  Testing on patients has shown 
these have caused muscular and skeletal pain in multiple patients, which seems to be 
related to the dosage level105,106.  However, if the MMP inhibitors had their structures 
altered to create a specificity of targets to cut down on toxicity, they would likely have 








Figure 9.  Batimastat structure102. 
 
 
New Generation Hydroxamate-Based MMP Inhibitors 
 
MMI-270 (See Figure 10) is likely the single most important structure from earlier 
generations that has carried over.  The molecule allows for a number of key benefits 
including water solubility, oral availability, and low molecular mass in a broad spectrum 
inhibitor.  However, they do have a noticeable limitation of drug metabolism. The 
metabolism issues stems from amide reduction resulting in the loss of the hydroxamate 
zinc-binding group, leading to hydrolysis to the carboxylate, then conjugation to 
glucuronide107. 
 
Angiotensin Converting Enzyme Inhibitors (ACEI)  
and Angiotensin Receptor Blockers 
 
Blood pressure is another factor that is important to consider when examining 






Figure 10.  MMI270 (CGS27023A) structure108. 
 
 
mechanisms of action of ACEIs are not known, they do affect aneurysm progression 
according to several studies.  Treating experimental animals with Angiotensin-II has been 
shown to decrease elastin content in the AAA and aortic wall109.  Additionally, collagen 
production in the vascular wall increases and arterial wall size decreases in established 
AAA patients when they are given ACEIs110.  Furthermore, research by Liao et. al, has 
shown that by using different ACEIs, elastin decreases could be controlled independently 
of arterial blood pressure lowering while preventing changes in inflammation of aortic 
wall111.  Another study conducted by Alsac et. al., testing an ACEI, perindopril, 
demonstrated its ability to reduce aneurysm growth through both the inhibition of MMP 
synthesis and changing elastin levels 112.  ACEI treatments have also been shown to limit 
aneurysm ruptures compared to no treatment in clinical trials, which other blood pressure 
lowering drugs including beta-blockers, calcium channel blockers, antagonists of 
angiotensin-II receptors, and diuretics have been unable to do113.  Unfortunately, studies 




from the UK on 1700 patients actually found that the aneurysm growth rate was higher in 
patients who had the ACEI treatment than those that did not114.  Due to these findings, it 
is clear that there is a need for more randomized studies in order to understand the true 
nature of ACEIs and what their actual therapeutic benefits are. 
As mentioned above, angiotensin II-receptor antagonists (ARBs) are blood 
pressure lowering drugs, but they also have been tested for their potential of preventing 
AAA growth115.  Using an experimental model in which apolipoprotein deficient mice 
were subjected to the chronic release of angiotensin II until their aortas dilated and 
eventually ruptured, researchers found that the administration of losartan was able to 
prevent aneurysm formation.  Further, they found when transforming growth factor-B 
was antagonized by losartan, progressive matrix degradation was prevented.  With these 
promising results, the need for more studies, clinical especially, to determine their ability 
to prevent AAA growth is obvious116. 
 
Natural Substances  
 
Some natural substances have been used to treat AAA.  Vitamin E improved 
AAAs and reduced the combined end point of fatal+nonfatal aortic rupture in Ang II 
animal model117.  Periadventitial administration of PGG(a polyphenol) delays the 




Polyphenols are a large and varied family of natural substances.  They exist as 




one or more hydroxyl function and are derived from the metabolism of either polyacetate 
or shikimic acid.  They are present in all vascular plants and are secondary metabolites. 
Currently, thousands of polyphenolic compounds have been studied in plants and 
they been grouped into classes.  These classes are broken down based on the variations in 
the basic chemical makeup that lead to differences in the methylation, oxidation, 
hydroxylation, and glycosylation, as well as their links to other secondary metabolites or 
primary metabolites such as carbohydrates, proteins, and lipids118.  Polyphenols consist of 
a hydrophobic core surrounded by phenolic (-OH) groups on the exterior of the 
compound.  This structure allows them to be broken down into condensed, complex or 
hydrolysable varieties.  They can also be divided into ligands, flavonoids, phenolic acids, 
and stilbenes based on the number of phenolic rings and their accompanying structural 
elements119.  To create hydrolysable tannins, gallic acid (3, 4, 5-trihydroxyl benzoic acid) 
must be esterified to a core polyol. If a more complex hydrolysable tannin is desired, the 
galloyl groups can be either esterified or oxidatively crosslinked.  Gallotannins, the 
simplest of the hydrolysable tannins, are merely polygalloyl esters of glucose, and 
pentagalloyl glucose (β-1,2,3,4,6-Pentagalloyl-O-D-Glucopyranose) is the most 
prototypical of these 117.  Pentagalloyl glucose (PGG) is comprised of five identical ester 
linkages which involve the core sugar’s aliphatic hydroxyl groups (See Figure 11).  
PGG’s alpha anomer is not common in nature, but PGG does have numerous isomers, as 
do the rest of gallotannins.  All of these isomers have a molecular weight of 940 g/mol.  
What vary based on the different structures of the isomers are the biochemical properties, 






Figure 11.  PGG structure120. 
 
 
chromatographic behavior.  While PGG is best known for its anti-oxidant properties, its 
elasto-regenerative properties have been demonstrated both in vivo and in vitro121-123.  
Systemic delivery of the aforementioned drugs has failed to translate into 
significant clinical advances.  Systemic toxicity and low concentration of drug delivered 
to the diseased area could possibly be the main reasons behind this failure.  To address 
these issues we need a targeted drug delivery system.  This offers an efficient drug 
loading in a biodegradable polymer with an increased circulation time in vivo to reach 
targeted sites and remaining at the site by specific chemical bonds and finally offering the 
release of the encapsulated drug in a controlled fashion.  Such a delivery system also 






Use of Nanoparticle Based Theranostic 
Agents in the Vascular Diseases 
 
Nanotechnology that has the potential to fight cardiovascular diseases by making 
an immediate impact can be divided into four categories.  First, tissue engineering using 
nanofibers can be used to rebuild damaged or lost tissue, for example allowing for the 
replacement of defective heart muscle125 or blood vessels126.  Second, molecular imaging 
paired with nanotechnology based agents can be used to identify, diagnose and track 
diseases127.  Nano-based carriers can be used as targeted therapeutics which allow for 
precise treatments, limiting drug side effects and ensuring the injured area receives the 
drug.  Finally, nanotechnology can be used to improve diagnostic devices, including 
implantable biosensors, allowing for better feedback and control as to what is occurring 
in the body.  Targeted nano therapeutics in cardiology are especially helpful because 
injections of nano particles do not put the patient at risk of embolism formation, like the 
larger particles associated with intravenous delivery (IV)128.  
 
Targeted Drug Delivery 
 
The ability to send drugs, using a nanocarrier to the site of injury as opposed to 
systemic or more generalized treatments, is currently the ultimate goal of pharmaceutical 
research129.  Targeted drug delivery serves to maximize the benefits of a drug because of 
the localization of the therapeutic pharmacological activity to the specific tissue or organ 
in need.  The encompassing idea of targeted drug delivery is to use various systems, 
physical, biological, molecular, in order to increase the concentration of the active agent 




treatment efficacy and decreasing drug toxicity130.  While drug delivery is excellent in 
theory, putting it into practice is much more challenging. In order to successfully execute 
targeted drug delivery, careful consideration must be made as to the metabolism and 
reactivity of the drug, as well as how the distribution and rate need to occur131.  Other 
important concepts that need to be considered are nanocarrier biocompatibility, local 
blood flow, amount and distribution of drug receptors, interactions of nearby biological 
and cellular membranes with nanocarrier and the ability of enzymes to metabolize the 
nanocarrier132 133.  
Biological nanocarrier which are developed around the use of antibodies on 
surface, sound very effective theoretically; however, in practice, they encounter some 
issues centered around the antibody-polymer conjugate’s distribution134.  These issues 
include problems with the polymer carrier capacity of the antibodies conjugation sites 
and changes to the antibody’s specificity based on the polymer molecules being 
conjugated.  Thus far, the final issue has been the largest antagonist of achieving 




Polymeric particles are the most heavily researched organic nanoparticles because 
of their ability to hold many types of drugs, release them over an extended amount of 
time and ease of linking targeting ligands to the surfaces136.  Polymeric particles are also 
very stable in both in vitro and in vivo settings.  Additionally, polymers have long been 
used in medicine137, including medical devices.  Another advantage of polymers like 




(PLGA), their co-polymer, is their biodegradability, which is very desirable for delivery 
applications138.  Poly-anhydrides and poly-orthoesters are also biodegradable, and been 
used for nanoparticle synthesis.  When hydrophobic polymers such as the ones stated 
above are combined with hydrophilic polymers their co-polymers are effective in 
synthesizing carriers of drugs139.  Poly-ethylene oxide (PEO), poly-propylene oxide 
(PPO), and poly-ethylene glycol (PEG) are all common copolymers used for this purpose.  
Another type of polymer used in drug delivery is responsive polymers, because they are 
able to react to temperature, pH, electromagnetic radiation, and other stimuli140.  The 
benefit of enclosing drugs within nanoparticles is two-fold.  First, the drug is protected 
from potential degradation by enzymes or hydrolysis, in both in vivo and in vitro 
conditions141.  Secondly, the encapsulation allows for flexibility in delivery techniques, 
allowing for more patient friendly approaches such as oral administration of insulin using 
polymer-based nanoparticles142.  Most types of substances, including RNA, DNA143, 
proteins, and peptides144, can be contained in these nanocarriers.  Furthermore, these 
carriers can be used for either specific targeting or simple localized delivery145.  When 
they are used as treatment for cancer, the particles are specifically designed to be small 
and hydrophilic increasing the time they remain in blood.  Because of the enhanced 
permeability and retention (EPR) effect seen in tumors due to blood vessel leakage or 
limited lymphatic drainage, the nanoparticles accumulate within the tumor146.  Mucosal 
surfaces are another common area in which localized release methods are used.  Eyes, 
lungs, nose, the gastrointestinal tract, and others are the target of particles coated with a 




stabilizes the drug during interactions with digestive enzymes.  Active targeting typically 
functionalizes the surface of the nanoparticles using anything from receptor binding to 
peptides to antibodies and others in order to ensure delivery to the targeted tissue 147.  
Human serum albumin nanoparticles created to allow for loperamide transport across the 
blood-brain barrier are a perfect example of this active targeting.  The nanoparticles are 
attached to transferrin or monoclonal transferrin receptor antibodies so that they can 
reach the transferrin receptor in the brain148.  In summation, all the developments in 
targeted drug delivery, specifically the advances in the use of nanoparticles, allow for 
better treatments and reduced systemic toxicity during treatments149,150. 
 
Bovine Serum Albumin (BSA) Nanoparticles 
 
Albumin has long been the standard for modeling protein behavior in sustained 
release drug delivery systems because of its stability and commonality.  This globular 
protein is also biodegradable, nontoxic, and non-antigenic, making it a great candidate for 
use in controlled drug delivery151.  Abraxane®, an albumin-bound nanoparticle loaded 
with Paclitaxel, is a successful example of this, having been approved in 2006 to treat 
metastatic breast cancer by the Food and Drug Administration (FDA)152.  Molecularly, 
albumin is made up of six subdomains and six sites for fatty acids to bind.  Hydrophobic 
drugs, including curcumin, are also capable of binding to these fatty acid sites, offering 
protection from degradation and thus making them more bioavailable153.  BSA particles 
usually use glutaraldehyde as a cross linker and are prepared by a process of coacervation 




options for cross linking have been suggested and include polyethyleneimine (PEI), 




Pharmaceutical nanoparticles, or nanocarriers, are essentially submicron sized 
particles that serve to hold and/or transport a drug.  Based on their target or usage, they 
are between 10 and a few hundred nanometers and are either dry, solid particles or 
colloidal dispersions155.  
Particle size affects degradation, targeting, clearance and uptake mechanisms 
156,157.  A reduction in particle size allows an improved dissolution rate and maximizes 
how much drug is available for absorption.  Nanoparticles for drug delivery can be 




Surface modification to the nanocarrier allows for increased residence time in 
blood158.  The particles are administered intravenously and do not dissolve immediately, 
an immune response (opsonization) to the blood proteins that are absorbed onto the 
particles’ surface will occur159.  The particles will then be quickly removed from 
circulation by the mononuclear phagocyte system (MPS) which will consume and 
dispose of the particles, eliminating therapeutic effects160.  Opsonization can be staved off 
by either a non-covalent attachment of polymers or surfactants to the nanocarriers’ 
surface, or molecular covalent attachments to the surface.  Poly-ethylene glycol (PEG)161 




on bovine serum albumin (BSA) loaded poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles, a steric PEG coating increased the half-life of the particles from 13.6 min 
to 4.5 hrs.150.  
 
Particle Charge (Zeta Potential) 
 
While surface coatings like PEGylation can improve the efficacy of nanoparticles, 
changing the charge of the nanoparticle can have major effects as well162.  Changing 
charge is well documented to alter protein adsorption and cellular internalization during 
circulation163.  This is reflected in the fact that nanoparticles that are positively charged 
have higher rates of phagocytosis than neutral and negatively charged particles, 
decreasing their blood circulation half-life150.  Another study determined that endosomes 
were more likely to escape due to surface charge.  Those results were based on the 
behavior of negatively charged polystyrene nanoparticles that stayed in endosomal 




 There have been a few studies that have successfully targeted AAA using 
diagnostic or therapeutic targeting. Small AAA can be diagnosed using a novel, 
noninvasive technique if nanoparticles can enhance visualization. Bonnard et al. managed 
to successfully target AAA via P-Selectin, expressed by activated platelets in AAA, by 
using microparticles functionalized by fucoidan. Two weeks after elastase perfusion, the 
microparticles, injected into rats via penis vein, were radiolabeled with 99mTc. Single 




image AAA165.  Another group proved that surface functionalization of doxycycline 
loaded PLGA nanoparticles with cationic amphiphiles can be useful in targeting AAA.  
These particles bind to elastin via hydrophobic interactions in cell culture of aneurysmal 
smooth muscle cells166.  AAA was successfully targeted via anti-elastin decorated 
nanoparticles in different animal models of AAA.  These nanoparticles could target 













Up to 90% of detected AAAs are small enough that they do not require surgery. 
However, they are not treated because there are no current pharmacological treatments to 
prevent AAA expansion approved by the FDA. A safe treatment that could prevent the 
expansion of small AAA would benefit many patients who are left to wait until their 
AAA grows large enough to require surgery. Our intention is to develop a minimally 
invasive, non-toxic, biodegradable vascular delivery system that targets AAA in order to 
prevent elastin degradation and regenerate elastin as a novel AAA therapy.   
 
Filling in the Knowledge Gap 
 
We have developed a nanoparticle system that has been functionalized with an 
elastin antibody, in order to achieve our goal. This system can recognize and bind to 
damaged elastin in the aorta when delivered systemically. We then load a MMP inhibitor 
and deliver it to the site of AAA and confirm the MMPs activity suppression.  Later, we 
will use an elastin regenerator instead of a MMP inhibitor to see the effect of elastin 
preservation in AAA therapy.  Finally, in order to provide a therapy for a more advanced 
AAA, where calcification is involved, we will deliver calcium chelator to site of the AAA 











To investigate whether MMP inhibitors like batimastat (BB-94) loaded 
nanoparticles (NPs) can be targeted to the site of abdominal aortic aneurysm (AAA) and 
whether they can stop growth of AAAs by suppressing local MMPs activity in a calcium 




We will optimize loading of BB-94 in PEGylated poly-lactic acid (PLA) NPs that 
are conjugated with anti-elastin antibodies, necessary for targeting damaged elastin.  We 
will study drug loading efficiency, in vitro release, drug activity, and cellular uptake of 
NPs.  NPs with optimum drug loading and release profile will be delivered intravenously 
in rats where AAAs have been created by perivascular application of calcium chloride.  
We will study the MMPs activity and AAA growth suppression with time.  We will also 




Several clinical trials for systemic MMP inhibition as a cancer treatment failed 
because of poor bioavailability, dose limiting toxicity, and systemic side effects, such as 
musculoskeletal problems, which limited the dose that could be tolerated168.  Clinical 
trials of systemic delivery of MMP inhibitor beta-blocker-propranolol did not show 
significant changes in the growth rate of aneurysms, but caused systemic side effects and 




for AAA.  The side effects caused by MMP inhibitors in cancer patients led to the use of 
substantially lower doses of MMP inhibitors in clinical trials for aneurysm prevention 170.  
Because our targeted treatment’s site-specificity permits very low doses of the drug, such 
therapy will be an attractive option for preventing expansion of aneurysms in patients 




To investigate whether PGG loaded nanoparticles (NPs) can be targeted to the site 
of an AAA and whether they increase elastin matrix deposition, thus allowing AAA 




We will optimize loading of PGG in bovine serum albumin (BSA) NPs that are 
conjugated with anti-elastin antibodies.  We will study drug loading efficiency, in vitro 
release, drug activity, and cellular uptake of NPs.  We will study in detail about elastin 
morphology, degradation, and regeneration by fastin and desmosine analyses and by 
transmission electron microscopy (TEM) and histology.  Using ultrasound imaging, 
mechanical properties of the aorta will be assessed to see whether elastin regeneration 
helps biomechanically to restore arterial function.  As calcification is seen in AAAs, we 
will also test if duel therapy of EDTA NPs to remove calcium and PGG NPs to restore 









It has been established that elastin degradation is a primary cause of AAA171, and 
whether AAA is large or small, regression of it and restoration of normal arterial 
architecture would be preferable.  Although no one previously could show elastin 
regeneration, our group demonstrated the protective effect of PGG in terms of protecting 
damaged and non- damaged elastin from protease degradation and the ability of PGG to 
help tropoelastin molecules to assemble and make new crosslinked elastin by vascular 
smooth muscle cells121.  We have already developed NPs that target to AAA.  We would 
like to use these NPs to deliver PGG at the site of aneurysms.  Such site-specific targeting 
of PGG would help arterial elastin restoration.  With the regeneration of elastin, we can 




To investigate whether elastin-specific vascular calcification associated with 
AAA can be first removed when targeted nanoparticles deliver chelating agent EDTA to 





In the rat model of calcium chloride, NP based EDTA therapy will be optimized 
and NP based PGG will be used.  We will create a moderate stage aneurysm and will 
treat them first with EDTA nanoparticles.  After that, we will treat them with PGG 




elastin regeneration by desmosine analysis.  Circumferential strain of the aorta will be 





Degeneration of elastin plays a crucial role in the pathology and progression of 
AAA, a disease characterized by the loss of structural integrity of the arterial wall.  AAA 
is often associated with calcification, which increases the risk of AAA rupture 4.  Current 
option for AAA is the replacement of weakened aorta with a vascular graft.  Our group 
has shown earlier that treatment with pentagalloyl glucose (PGG) increased elastin matrix 
deposition by healthy and aneurysmal vascular smooth muscle cells in vitro 121.  
Furthermore, we have shown that EDTA nanoparticles can remove calcification from 
calcified artery with minimal dose of EDTA using the same nanoparticles technology 172.  
We would like to use combination therapy of EDTA and PGG to be delivered at the site 
of aneurysms.  Such dual therapy of EDTA followed by PGG would help reduce 








PREVENTION OF ABDOMINAL AORTIC ANEURYSM PROGRESSION BY 
TARGETED INHIBITION OF MATRIX METALLOPROTEINASE ACTIVITY  







The side effects caused by MMP inhibitors in cancer patients led to the use of 
substantially lower doses of MMP inhibitors in clinical trials for aneurysm prevention.  
Clinical trials of systemic delivery of a MMP inhibitor, propranolol—which is a beta-
blocker—did not show significant changes in the growth rate of aneurysms, but caused 
systemic side effects and reduced patient compliance, thus dampening enthusiasm for 
pharmacological therapy for AAA.  Because our targeted treatment’s site-specificity 
permits very low doses of the drug to be used, this therapy will be an attractive option for 




Our previous study showed that poly D, L-lactide (PLA) nanoparticles (NPs) 
conjugated with an anti-elastin antibody can be targeted to the site of an aneurysm in a rat 
model of AAA.  Here, we tested whether such targeted NPs can deliver the MMP 
inhibitor batimastat (BB-94) to the site of an aneurysm and prevent aneurysmal growth. 
 
Approach and Results 
 
BB-94-loaded PLA NPs-targeted to the aneurysmal aorta were studied in a 




conjugated BB-94-loaded NPs (EL-NP-BB94) targeted the site of aneurysms and 
delivered BB-94.  Such targeted delivery inhibited MMP activity, elastin degradation, 
calcification, and aneurysmal development in the aorta (269% expansion in control vs. 
40% EL-NP-BB94) at a low dose of BB-94.  The systemic administration of BB-94 alone 




Targeted delivery of MMP inhibitors using NPs may be an attractive strategy to 




Abdominal aortic aneurysm (AAA) characterized by dilation of the abdominal 
aorta, is one of the top-10 causes of death among older men.173  Although the cause of 
AAA remains unknown in the majority of cases, several key regulators of AAA 
pathogenesis are known.  Matrix metalloproteinases (MMPs) have been shown to play a 
major role in progressive extracellular matrix (ECM) degradation in AAA.174,175.  Under 
inflammatory conditions, infiltrating macrophages, vascular smooth muscle cells, 
endothelial cells, and adventitial fibroblasts secrete pro-MMPs; cleavage of the pro-MMP 
subunit activates the MMPs, causing ECM degradation.  MMP activity may be naturally 
suppressed by tissue inhibitors of matrix metalloproteinases (TIMPs), which comprise a 
family of four protease inhibitors:  TIMP1, TIMP2, TIMP3, and TIMP4.176.  An improper 




several vascular conditions, such as AAA, atherosclerosis, hypertension, and 
calcification.177 
Several types of MMPs are expressed in AAA tissue, including MMP-1, MMP-2, 
MMP-3, MMP-9, and MMP-12.78 MMP-9 and MMP-2 knockout mice do not develop 
aneurysms, suggesting that these MMPs play a major role in the development of AAA3.  
A number of synthetic MMP inhibitors (e.g., doxycycline- and hydroxamate-based) are 
known to decrease MMP activity178 and prevent medial destruction.179.  Synthetic MMP 
inhibitors with a hydroxamate (-CONHOH) group bind zinc atoms and suppress MMP 
enzymes180.  Among the many hydroxamate-based MMP inhibitors are marimastat, 
solimastat, prinomastat, cipemastat, and Batimastat (BB-94)181,182.  It has been shown that 
BB-94 was one of the first synthetic MMP inhibitors to be tested clinically to reduce 
MMPs in cancers with advanced malignancies183.  However, its effectiveness is limited 
by its poor water solubility when administered orally, requiring parenteral administration. 
In several studies, systemic administration of MMP inhibitors effectively reduced 
aneurysmal onset in animal models182,184, but systemic delivery can cause off-target 
inhibition of the MMP activities essential for normal homeostasis185.  Although there are 
no in vivo studies of targeted delivery of MMP inhibitors to the aneurysm site, a recent in 
vitro study showed the potential of delivering doxycycline-loaded nanoparticles (NPs)  
for localized elastic matrix stabilization and regenerative repair in AAA166.  Doxycline 
was also shown to reduce mRNA stability for MMP-2 and inhibit MMP activity that way186.  
In this study, we tested the hypothesis that systemic delivery of elastin-antibody 




the aneurysm site, will slowly release the drug at the aneurysm site, and inhibit local 
MMP activity and subsequent aneurysms.  Such targeted MMP inhibition would require 
smaller and less frequent drug doses than systemic administration, which would minimize 
systemic side effects. 
 
Materials and Methods 
 
Synthesis of Batimastat-Loaded Nanoparticles (EL-NP-BB94) 
 
Poly (D,L-lactide) (PLA) NPs were prepared using the solvent-diffusion-based 
nano-precipitation method.167  PLA (10 mg, average MW 75k-120k) (Sigma Aldrich, St. 
Louis, MO) was dissolved in 1 ml acetone (VWR International, Radnor, PA).  1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol) – 2000) 
(2 mg, DSPE-PEG (2000) Maleimide, Avanti Polar Lipids, Inc., Alabaster, AL) and BB-
94 (Sigma Aldrich, St. Louis, MO) were dissolved in dimethylsulfoxide (Sigma Aldrich, 
St. Louis, MO), and this solution was then added to the PLA solution.  The polymer 
solution was added drop-wise (16 µl/sec) to water and kept under sonication (Omni 
Ruptor 4000) for 20 minutes at 4°C.  Following sonication, the particles were washed 
twice with distilled water by centrifugation at 14000x g for 30 minutes at 4°C and then 
re-suspended in distilled water.  The non-solvent (water) to solvent (acetone) ratio was 
1:15 for all experiments.  Three different batches containing ratios of 5:1, 10:1, and 15:1 
polymer to BB-94 were prepared in which the ratio between the two polymers (PLA:  








The total final dry weight of the NPs was recorded, and NP yield was calculated 
using the formula shown below: 
 
 
Nanoparticle Characterization  
 
Particle size, ζ-potential and Transmission Electron Microscopy (TEM) were 
performed to characterize the NPs.  The NP suspension (1 mg) was diluted in HPLC-
grade water, and the ζ-potential and particle size were measured with a 90Plus particle 
size analyzer (Brookhaven Instruments Co., Holtsville, NY).  Transmission Electron 
Microscopy (TEM) was used to study NPs morphology.  A drop of 0.1 mg/ml NPs-water 
suspension was placed on a formvar-coated copper grid and dried overnight in vacuum 
desiccator.  Grid-mounted samples were imaged using a Hitachi H7600 TEM. 
 
Nanoparticle Degradation Studies 
 
Blank NPs were suspended in phosphate buffered saline (PBS) and stirred at 37oC 
to test the polymer degradation.  Degradation of the NPs was monitored by measuring the 
weight of the remaining NPs at different time points (1, 7, 14, 21, and 28 days) after 
lyophilization.  The percent weight loss was calculated using the difference between the 
remaining dry weight and the initial weight.  We also tested blank NPs degradation by gel 
permeation chromatography (GPC). Nanoparticles (5 mg) were suspended in 5 mL of DI 
water at stirred at 37oC.  At week 1 and week 4, NPs were isolated by filtration and 




solution was filtered directly into chromatography vials using 0.2µm PTFE filters.  
Polymer molecular weight was assessed by Size Exclusion Chromatography/Gel 
Permeation Chromatography(SEC/GPC) using a Shodex KF-804L column on a Waters 
HPLC/GPC system equipped with an Autosampler, column heater, and refractive index 
(RI) Detector.  Chloroform was used as the mobile phase at a flow rate 0.65 ml/min, and 
the column was kept at 30°C during all separation runs.  The injection volume for GPC 
analysis was 50 µL.  Polystyrene standards of 9, 35, 50, 100 and 200 kDa were used as 
markers, and a control sample of PLA (Average MW 75,000-120,000 kDa) was used to 
validate the calibration curve reliability. 
 
Loading Efficiency and Release Profile of BB-94  
 
Loading efficiency was calculated by dissolving NPs in dimethylsulfoxide, 
determining BB-94 concentration at λ (max) = 285 nm using UV spectrophotometry, and 
using the equation shown below: 
 
 
To study release kinetics, a known amount of NPs was suspended in phosphate 
buffered saline (PBS) and incubated at 37°C on a shaker.  Suspensions were centrifuged 
for 30 minutes at 10000×g at room temperature (RT).  The supernatant was removed, and 
the sediment was freeze-dried and characterized for BB-94 concentration by dissolving it 
in 100 µl dimethylsulfoxide and measuring absorbance by UV spectrophotometry. 





Conjugation of Elastin Antibody to NPs 
 
Traut’s reagent (34 µg, G-Biosciences, Saint Louis, MO) was used for thiolation 
of 10 µg of rabbit anti-rat elastin antibody (United States Biological, Swampscott, MA), 
and the mixture was incubated in HEPES buffer (20 mM, pH=9.0) for an hour at room 
temperature.  Thiolated antibodies were rinsed with HEPES buffer and added to the NPs 
(4 µg antibody per 1 mg NPs) and then incubated overnight for conjugation.  After 
incubation, antibody-conjugated NPs were washed twice with PBS, centrifuged (10000 
rpm for 10 minutes), and suspended in 0.3% rat serum albumin for an in vivo study 




To test if the BB-94 loaded in the NPs was still in active form, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography was performed.  
Briefly, NPs were dissolved in dichloromethane (Aldrich, MO) and DI water at a ratio of 
3:1.  This mixture was mixed vigorously and centrifuged for 10 minutes at 10000×g to 
extract BB-94 from the NPs.  The DI water containing BB-94 was subsequently collected 
and lyophilized.  The activity of the extracted BB-94 from the NPs was tested by two 
different methods. In the first approach, culture medium collected from rat aortic smooth 
muscle cell (RASMC) cultures was loaded into a SDS-PAGE zymography gel, and 
extracted BB-94 was added to the development buffer(500ng/ml) (50 mM Tris Base, 5 
mM CaCl22H2O, 200 mM NaCl, 0.02% brij 35).  After 24 hours incubation in the 
development buffer, gels were stained with 0.5% coommasie blue for an hour at room 




this, the gels were photographed using epi-illuminated white light in a Bio-Rad Gel Doc 
instrument.  Zymography bands were quantified using Image J software and data was 
reported as RDU. In the second approach, BB-94 activity was tested in RASMCs 
cultures.  Briefly, RASMCs were grown to 80% confluency at 37°C and 5% CO2 in 
DMEM containing 10% FBS and 1% penicillin-streptomycin (ScienCell Research 
Laboratories, Carlsbad, CA).  After 24 hours, cells were treated with extracted BB-94 
(500 nM) in serum-free medium for 24 hours.  After treatment, conditioned medium was 
collected.  The total protein of the culture medium was quantified using Bicinchoninic 
Acid (BCA) protein assay (Pierce, Rockford, IL) with 10 µg total protein loaded per well 
and prestained molecular weight standards (Precision Plus Protein Standard, Bio-Rad, 
Hercules, CA).  Gel zymography was performed as described in the previous section. 
 
Reverse Zymography for TIMP Activity 
 
Equal amounts of protein from RASMC-conditioned cell culture media (BB-94 
treated or control) were loaded in 15% reverse zymogram gel containing 1.5% gelatin 
and collagenase (20 units) under nondenaturing and nonreducing conditions.  After 24 
hours incubation in the development buffer, gels were stained with 0.5% coommasie blue 
for an hour and were destained.  The gel pictures were captured using epi-illuminated 
white light and a Bio-Rad Gel Doc instrument; bands were analyzed and quantified using 








RASMCs and Rat Aortic Endothelial Cells (RAOEC) 
 
A standard MTT assay was performed to measure the cytotoxicity of NPs to 
RASMCs and RAOECs.  RASMCs and RAOECs were cultured with NPs for 24 hours.  
MTT colorimetric assays (Sigma Aldrich, St. Louis, MO) were performed according to 
the manufacturer’s protocol to confirm cell viability.  Control and NP-treated cells were 
washed with PBS and incubated for 3 hrs. with 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (5 mg/ml).  Formazan crystals formation 
was detected at 570 nm and viability was shown as % MTT reduction compared to 
control.  MTT activity was normalized to control. 
 
Elastin-Antibody Conjugated Nanoparticle Uptake by Macrophages 
 
Elastin-antibody conjugated NPs were loaded with fluorescent dye, 1, 1-
dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide (DIR), as described 
previously167.  Macrophages (RAW 264.7, ATCC® TIB-71™) were grown in 24-well 
tissue culture plates followed by incubation with EL-DIR-NPs (1 mg/ml) at 37°C in 5% 
CO2 for 4 hours and 24 hours.  Cells were washed three times with sterile PBS and 
imaged before and after washing using EVOS® XL Cell Imaging System to determine NP 
uptake.  As controls for charge and size, we prepared two different batches of NPs, one 
with positive surface charge and one with smaller NP size.  To create a positive surface 
charge, NPs were coated with chitosan187 (molecular weight 600K-800K) (ACROS, NJ).  
To study cytotoxicity, rat bone marrow macrophage cells (Cell Biologics, Inc., RA-
6030F) were grown in 24-well tissue culture plates followed by incubation with BB94 




Feasibility of Nanoparticle Targeting in vivo  
 
Local elastin damage in the rat abdominal aortic region was induced by 
perivascular application of calcium chloride.69  After ten days, rats were divided into two 
groups and went through treatment with batimastat loaded NPs or blank NPs.  Briefly, 19 
male Sprague-Dawley (SD) rats (5-6 weeks old) were placed under general anesthesia 
(2% to 3% isoflurane).  The infrarenal abdominal aorta was exposed and treated 
periadventitially by placing 0.50 mol/L CaCl2-soaked sterile cotton gauze on the aorta for 
15 minutes.  The treated area was flushed with warm saline, and the abdominal incision 
was closed with sutures.  Animals were allowed to recover and were given a normal diet 
for ten days.  Adventitial inflammation and elastic lamina degradation has previously 
been shown to occur within ten days in this model.  NPs loaded with BB-94 and 
conjugated with elastin antibody (named EL-NP-BB94 henceforth, ~10mg/kg body wt.) 
were suspended in 200 μl of 0.3% rat serum albumin (Sigma Aldrich, St. Louis, MO) and 
were injected through the tail vein (n=5).  Control animals received elastin antibody-
conjugated blank NPs (named EL-NP-Blank henceforth) (n=5).  Three additional rats 
were injected with elastin antibody conjugated and DIR dye-loaded NPs (named EL-NP-
DIR henceforth) to monitor delivery of the NPs by in vivo imaging.  As a negative 
control, IgG antibody-conjugated NPs loaded with DIR dye (named IgG-NP-DIR 
henceforth) were injected through the tail vein (n=3).  To study if the systemic delivery of 
low-dose BB-94 affects MMP activity in the aorta, three rats received the same amount 
of BB-94 (600 µg of BB-94 /kg body wt.) dissolved in 200 µL PBS solution with 0.01% 




Two days (48 hrs.) after treatment, the rats were euthanized and thoracic and 
abdominal aortic tissue segments were explanted and snap-frozen in liquid nitrogen.  
Total protein from the aortic samples was extracted by pulverizing liquid nitrogen-frozen 
tissue samples and homogenizing them in RIPA extraction buffer (50 mM Tris-HCl pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% 
SDS, with protease inhibitor cocktail) (Roche Diagnostic GmbH, Germany) according to 
the manufacturers protocol.  Sections of thoracic and abdominal aortic tissue were 
embedded in Optimal Cutting Temperature compound (OCT) for cryostat sectioning.  For 
DIR-loaded NP groups, whole fresh aorta and all organs were harvested and imaged 
using Caliper IVIS Lumina XR (Hopkinton, MA) with Ex/Em of 745/795 nm for 
studying targeting and bio distribution of NPs.  
 
MMP Activity in Rat Aorta 
 
The total protein from the harvested aortic tissue after 48 hours of treatment was 
quantified using the BCA protein assay kit (Pierce, IL).  An internally quenched peptide 
substrate, which is specific to MMP-2 and 9 (excitation 280 nm, emission 360 nm, MMP 
Substrate III, Anaspec, CA), was used to measure the MMP activity.  One mg of 
substrate dissolved in 50 µl dimethylsulfoxide was diluted in 10 ml of development 
buffer (50 mM Tris Base, 5 mM CaCl22H2O, 200 mM NaCl, 0.02% brij 35).  
Development buffer (96 µl) was mixed with 2 µl of the extracted protein along with 2 µl 
of substrate stock solution and incubated for one hour at 37°C.  Endpoint florescence 





Nanoparticle Targeting to Inhibit Aneurysm Progression 
 
To study long-term aneurysmal inhibition, another set of 13 rats was used.  AAAs 
were induced by perivascular application of calcium chloride69.  Ten days after injury, 
NPs (~10mg/kg body wt.) were injected via tail vein once a week for four weeks (n=5 
EL-NP-BB94, n=5 EL-NP-Blank, and n=3 EL-NP-DIR).  Rats were euthanized on day 
38, and organs and aorta were harvested. IVIS imaging was used to confirm targeting and 
bio distribution in the EL-NP-DIR group.  Aortic tissues from the EL-NP-Blank and EL-
NP-BB94 groups were harvested as described above. 
 
In situ Zymography 
 
To examine the activity of MMPs in the aortic tissue samples in situ, zymography 
was performed on histological sections of aorta isolated at 48 hours and 38 days after NP 
injection.  Gelatinolytic activity was demonstrated in unfixed cryostat sections (8 μm 
thick) using DQ-gelatin as a substrate (Life, IL).  Cryostat sections of the abdominal aorta 
were air-dried for 10 minutes.  One part DQ-gelatin (1 mg/ml of DI water) was mixed 
with nine parts 1% agarose (Promega, WI) in PBS containing DAPI (1 μg/ml) (Life 
Technologies, IL).  A drop of the mixture was added to each section, and each section 
was then incubated in development buffer for one hour at 37 C.  As a positive control, in 
one sample MMP activity was blocked by MMP inhibitor 1, 10-phenanthroline 
monohydrate (0.2mmol/L) (Life Technologies, OR).  Images were captured using 






Histological Analysis  
 
Formalin-fixed samples were embedded in paraffin, and 5 µm sections were 
mounted on glass slides and heated overnight to adhere the tissues to the slides and melt 
the paraffin.  Subsequently, the slides were deparaffinized with xylenes and graded 
ethanol and stained with hematoxylin and eosin for tissue morphology, Verhoeff-van 
Gieson (VVG) for elastic fibers, and Alizarin Red S with a Light Green SF counterstain 
for calcification.   
 
Immunostaining for Macrophages (CD80) 
 
 Aortic sections from the 38 day aneurysm study were used.  Tissues preserved 
with formalin were embedded in paraffin and sectioned as previously described.  
Subsequently, the slides were deparaffinized with xylenes and graded ethanol, and 
antigen retrieval was done using the HCl method.  The slides were incubated overnight at 
room temperature with the primary antibody, Mouse Anti Rat CD80 (Bio-Rad, Hercules, 
CA).  Subsequently, the slides were incubated for 1 hour with the secondary antibody, 
Cy7 goat anti-mouse IgG (H+L) (Bioss Inc., MA), and DAPI nucleic acid stain and then 
imaged with a fluorescent microscope, EVOS® XL Cell Imaging System.   
 
Aneurysmal Development  
 
Initial external diameter was measured at the time of the CaCl2 injury.  Final 
aortic diameter was recorded before euthanasia on day 38.  Aneurysmal development was 







In vitro experiments were performed in triplicate and repeated twice; for in vivo 
studies, five animals were used per group per time point.  Student’s t test was performed 
using Microsoft Excel, and exact permutation test was performed using the NPAR1WAY 
procedure in SAS.  The data are expressed as the mean ± standard deviation; results were 






NPs were prepared with three different initial BB-94 concentrations (5:1, 10:1, 
15:1 polymer-to-drug ratio).  No significant differences were found for the percent yield 
of NPs among the three batches.  Increasing the initial BB-94 concentration during NP 
preparation did not increase the final BB-94 loading in the NPs.  Particle-surface charge 
was dependent on initial polymer to BB-94 ratios.  All BB-94-loaded NPs were 
negatively charged; however, a higher polymer to BB-94 ratio led to a more negative 
surface charge (see Table 2). 
 
NP Degradation and BB-94-Release Study 
 
A higher polymer-to-BB-94 ratio led to a smaller NP size, which was confirmed 
visually by TEM (See Figure 12).   
When suspended in DI water, Blank-NPs lost substantial weight (65±4.5%) in 

















15:1 62.9± 33.9 5.7 ± 2.5 123.8 ± 24.9# -83.1 ±2.8#* 
10:1 44.2 ± 3 8.4 ± 2.7 153.5 ± 26.8# -47.2±5.5#* 
5:1 38.4 ± 18 6.7 ± 0.4 196.3 ± 3.3 -29.1±5.1 
 
*Represents statistical significance (Student’s unpaired t-test, P < 0.05),  
















This data was also corroborated by NP degradation seen in the GPC study.  
Polymer nanoparticles as prepared showed one broad peak at retention time at ~9 
min.  With time, low molecular weight products (with retention time ~12-13 min) 
appeared suggesting polymer degradation (See Figure 14). 
 In vitro BB-94 release from the NPs was gradual and lasted for up to eight days. 
Although final BB-94 loading was similar for all polymer-to-BB-94 ratios, the BB-94 
release profile varied with the starting BB-94 concentration (See Figure 15).  Slower 
release was observed in NPs with a 5:1 polymer-to-BB-94 ratio, while significant burst 
release was observed when the initial BB-94 concentration was lower (10:1 or 15:1 
polymer: BB-94 ratio).  BB-94 release was more controlled for the batch with a higher 
starting BB-94 concentration (5:1 polymer: BB-94 ratio), so these NPs were chosen for 
further study.  
 
Activity of BB-94  
 
The activity of the BB-94 loaded in the NPs was examined using gel zymography.  
When extracted BB-94 was added to the development buffer, pro-MMP-2 (72 kDa), 
active MMP-2 62kD), and MMP-9 (92 kDa) activities were inhibited completely (See 
Figure 16).  
When BB-94 extracted from the NPs was added to the RASMC cultures, ninety 
percent of MMP-9 (92 kDa) and ten percent of MMP-2 (62 kDa) activity were inhibited. 
Notably, more MMP-2 remained in the pro-form (inactivated, 72kD) when BB-94 was 







Figure 14.  GPC curves show peaks for degradation products at retention time (~13 min) 

















Figure 16.  Gel zymography study when BB-94 was used in development buffer. * 
(Student’s unpaired t test, P < 0.05) and # (exact permutation test, P < 0.05). (n=6 for 







Figure 17.  Gel zymography study:  Conditioned media. * (Student’s unpaired t test, P < 
0.05) and # (exact permutation test, P < 0.05). (n=6 for zymography). Dashed line 






There was no significant difference in the expression of tissue inhibitors of 
metalloproteinase-2 (TIMP-2) (21 kDa) between control and BB-94-treated cells (See 
Figure 18).  These results suggest that BB-94 loaded NPs inhibited MMPs without 
affecting TIMP-2 levels. 
 
NP Cytotoxicity and Cellular Uptake  
 
RAOEC and RASMC viability showed no significant change in 24 hours in the 
presence of NPs when compared to the control (See Figure 19A&B).  We have already 
shown that such NPs are not taken up by VSMCs167.  Inflammatory cells such as 
macrophages are commonly present at the site of AAA.  Thus, we determined if our NPs 
were resistant to macrophage uptake.  NPs labelled with a DIR dye were incubated with 
macrophage cell cultures for 24 hours (ζ-potential: -29.1±5.1, size: 196.28±3.2 nm).  Due 
to the negatively charged surface of the chosen NPs, no macrophage uptake was observed 
(See Figure 19-a1,a2,a3).  When the surface-charge was changed to positive with the 
addition of chitosan, (ζ-potential: +20.28±4.93), NPs could be seen in the cell cytoplasm 
which suggests that they were taken up by macrophages (See Figure 19C- b1,b2,b3).  
When NP size was changed to ~125 nm and the surface charge remained negative (ζ-
potential: -83 ±2.8), there was again significant uptake by macrophages (See Figure 19C- 
c1,c2,c3).  Overall, ~200 nm NPs with negative surface charge that were chosen for further 
studies were resistant to macrophage uptake.  Bone marrow macrophages viability 
showed no significant change in 24 hours for blank and BB-94 loaded NPs at thirteen 













Figure 19.  Cells viability and uptake in presence of NPs. * (Student’s unpaired t test, P < 





In vivo NP Targeting and MMP Inhibition  
 
 We have shown that NPs with a surface conjugated anti-elastin antibody can 
target the site of aortic injury in this animal model.167  We confirmed in vivo targeting, by 
observing localized fluorescence at the injury site of the abdominal aorta for the EL-NP-
DIR group, suggesting excellent targeting to the injured aorta (See Figure 20A), while no 
fluorescence was observed in the injured aorta for control IgG-NP-DIR group (See Figure 
20A).  
 We next examined if NPs loaded with BB-94 would target the injury site and 
inhibit local MMP activity.  Fluorescence intensity data when normalized to total protein 
content showed that the abdominal aorta had ~50% higher MMP activity than the 
thoracic aorta in the EL-NP-Blank group (See Figure 20B).  This result suggests that 
MMPs were activated by CaCl2-mediated injury and that blank NPs targeted to the 
abdominal aorta did not suppress MMP activity.  The EL-NP-BB94 group showed 56% 
lower MMP activity in the abdominal aorta in comparison to the thoracic aorta, 
suggesting that MMP activity was completely suppressed at the injury site (See Figure 
20B).  When the same concentration of BB-94 was delivered by intraperitoneal injection 
(IP), MMPs in the abdominal aorta showed 63% higher activity than the thoracic aorta, 
suggesting that systemic delivery of the same dose of BB-94 was ineffective in 
suppressing local MMP activity in the abdominal aorta (See Figure 20B).  These results 
were further confirmed by in situ zymography studies on histological sections of 






Figure 20.  Targeting and MMPs activity after 10 days. * (Student’s unpaired t test, P < 
0.05) and # (exact permutation test, P < 0.05) (n=5). Dashed line represents the mean 









enzymatic degradation of DQ gelatin, which directly corresponds to the MMP activity in 
the sections.  Intense green fluorescence corresponding to higher MMP activity was 
found in the sections of the abdominal aorta in the control animals receiving EL-NP-
Blank or IP injected BB-94 (IP-BB-94); a significant suppression of MMP activity was 
observed in the BB-94 NP group (EL-NP-BB94), (See Figure 20C).  This was similar to 
the positive controls, where MMP activity was inhibited by the addition of 1, 10-
Phenanthroline during in situ zymography.  
 
Long-term Targeting and Bio Distribution of NPs 
 
With encouraging results in the 48-hour targeting experiment, we next determined 
if such targeting can inhibit MMP activity and aneurysmal development for prolonged 
periods.  Because our BB-94-release study showed slow release for up to seven days, we 
decided to inject elastin-antibody conjugated NPs once weekly for four weeks.  After 
injections (4 injections over a total of 38 days after first CaCl2 injury), a three-fold 
increase was seen in the fluorescence signal in the abdominal aorta for the EL-NP-DIR 
group as compared to a single injection (Figure 21A compared to Figure 20A), indicating 
more NPs accumulated at the injury site.  The fluorescence signal of DIR (% 
florescence/dry weight of organ) increased in the abdominal aorta from 26.3 to 78.7%.  
At the same time, the signal decreased from 0.78 to 0.003% for the kidneys, from 15 to 
2.7% for the liver, and from 48 to 18% for the spleen in comparison to the 2-day study 
(Figure 21 B).  These data show that additional NPs accumulated at the injury site, while 






Figure 21.  Targeting after 4 weeks. Cross-section of abdominal aorta showing 
NPs(purple). Matrix metalloproteinase activity in abdominal aortic sections by in situ 







infiltrating from the adventitial side of the aneurysmal aorta through the vasa vasorum 
rather than from the luminal side and then attaching to the degraded elastic lamina deep 
within the medial layer (See Figure 21C).  
 
Long-Term Inhibition of MMPs and Aneurysmal Development 
 
 When NPs were injected weekly for four weeks after CaCl2 injury, MMP activity 
was still suppressed in animals receiving EL-NP-BB94 NPs (similar to the 48-hour 
study), while MMPs remained elevated in the EL-NP-Blank group (Figure 21D).   
  
 
Figure 22.  Histological analysis at 38 days. 
 
Hematoxylin and eosin staining showed significant inflammation in the adventitia in the 
EL-NP-Blank group, while the EL-NP-BB94 group maintained greater structural 
integrity and had little inflammation (Figure 22A and Figure 22E respectively).  
Verhoeff-van Gieson (VVG) staining revealed the elastic lamina was broken and 




NP-BB94 group (Figure 22B and Figure 22F). Similarly, alizarin red S staining showed 
heavy medial calcification in the EL-NP-Blank group and a substantial reduction in 
calcification in the BB94-treated group (EL-NP-BB94) (Figure 22C and Figure 22G).  
Macrophage immunohistochemistry revealed that the blank NPs group had a higher 
density of M1 macrophages in the adventitia and ruptured media in comparison to the 





 This study demonstrates that the use of targeted NPs carrying a potent MMP 
inhibitor can successfully inhibit local MMP activity in inflammatory vascular conditions 
such as AAA.  We optimized NP size, surface charge, and BB-94 loading. Our data agree 
with the literature:  During NP preparation, the particle size increased with increasing 
drug concentration and the negative surface charge decreased.188  Particle size and drug 
loading are important parameters that dictate the release of a drug from NPs.  The 
negative surface charge facilitates electric repulsion among NPs, thus increasing NP 
stability.189  Surprisingly, increasing initial BB-94 concentration did not lead to a higher 
amount of BB-94-loading, with the maximal loading being only 6-8% of BB-94 in PLA.  
This may have occurred due to the physical properties of the original drug.190  Although 
drug-loading was similar, drug dispersion within NPs, and thus ultimate release, varied 
with initial drug concentration.  Our study shows that higher polymer content (15:1 and 
10:1 polymer to BB-94 ratio) results in burst release on day 1.  This may have occurred 




polymer-to-BB-94-ratio batch had the biggest particle size and showed a more-controlled 
release because of either lower surface area or better drug encapsulation.  Our NP 
degradation data with blank NPs showed significant weight loss after 7 days and an 
increase in polymer degradation products as assessed by GPC, suggesting that drug 
diffusion and polymer degradation occurred simultaneously.  
Maintaining drug activity during NP synthesis is necessary for success in 
targeting.  We showed that BB-94 extracted from NPs suppresses MMP activity both in 
gel zymography and in cell cultures.  We found that BB-94 added to the development 
buffer during gel zymography was more effective in inhibiting MMPs (both the active 
and pro forms) than when it was added to cell culture media.  It is possible that BB-94 
dissociated during gel electrophoresis when the cell culture media was loaded in gels, 
thus causing lower MMP inhibition.  The findings from reverse zymography showed no 
significant difference in the expression of TIMP-2 protein within the groups; this is 
consistent with the literature showing that BB-94 has no effect on TIMPs.191  
Particle size and charge are important criteria in targeting NPs to the vasculature.  
It has been shown that NP-targeting of vascular ECM in an aneurysm site occurred for 
particle sizes below 200 nm.167  That study also showed that a negatively charged NP 
surface prevents NP uptake by vascular smooth muscle cells.  Because macrophages are 
phagocytic and present at the aneurysmal site, we determined if a negative surface charge 
would also prevent the uptake of NPs by macrophages.  We showed that macrophages do 




charge).  Based on these results and previous VSMC-uptake results, these NPs would 
remain in the ECM.  
Elastin-antibody conjugation on the NP surface also allowed us to target these 
NPs to the site of elastin damage found in the aneurysm site due to the fact that this 
antibody recognizes only core amorphous elastin that is exposed during elastic lamina 
degradation.167  Our data with DIR dye-loaded NPs confirmed that they targeted only the 
injury site while sparing the healthy aorta.  More importantly, we found that NPs entered 
preferentially from the adventitial side through the vasa vasorum and lodged deep in the 
media when delivered systemically.  This is clinically advantageous because the 
intraluminal thrombus generally present in an aneurysm can obstruct NP-targeting from 
the luminal side.  Notably, more degradation and inflammation is seen clinically in the 
adventitia.192 
MMPs, in particular MMP-9 (gelatinase B/92 kDa) and MMP-2 (gelatinase A/72 
kDa), play a significant role in AAA development and progression.78  The goal of 
targeted treatment is to suppress MMP activity at the site of AAA so that further ECM 
degradation can be prevented.  Our MMP fluorogenic assay showed that the MMP-2 and 
MMP-9 activity (represented as a ratio of abdominal aorta over thoracic aorta in the same 
animal) was 50% higher in the EL-NP-Blank and BB-94 IP groups, suggesting that 
sustained MMP activation was induced by CaCl2 injury and was not inhibited in the 
abdominal aorta by these treatments.  Only when BB-94 was delivered by targeted NPs 
(EL-NP-BB94) was a significant decrease in MMP activity seen in the abdominal aorta 




and inhibited local MMP expression.  This can occur by the suppression of macrophage 
activation as we have observed; this result is consistent with previous studies103.  These 
data are corroborated by the qualitative in situ zymography findings on histological 
sections of the abdominal aorta, which show suppression of gelatinolytic activity in 
tissues in the EL-NP-BB94 group alone 193.  Others have shown that a daily IP injection 
of 15 mg of BB-94 inhibited the expansion of AAA in elastase-induced aneurysms in rats 
However, the study lasted for only seven days, and AAA was treated only by the 
systemic inhibition of MMPs.  We show that targeted NPs with very low concentrations 
of BB-94 injected only once weekly (equivalent to 25 µg total BB-94/animal/day) can 
significantly inhibit aneurysm expansion in a four week study.  This corresponds to a 
580-fold lower BB-94 concentration than others have used systemically103.  Several 
clinical trials for systemic MMP inhibition as a cancer treatment failed because of poor 
bioavailability, dose limiting toxicity, and systemic side effects, such as musculoskeletal 
problems, which limited the dose that could be tolerated.168  The side effects caused by 
MMP inhibitors in cancer patients led to the use of substantially lower doses of MMP 
inhibitors in clinical trials for aneurysm prevention170.  The propranolol treatment was 
successful in aneurysm-prone turkeys and caused an increase in the tensile strength of 
tissue rings from the abdominal aorta.194  However, clinical trials of the systemic delivery 
of, beta-blockers like propranolol, did not show significant changes in the growth rate of 
aneurysms, but caused systemic side effects and reduced patient compliance11,169, thus 
dampening enthusiasm for pharmacological therapy for AAA.  Because our targeted 




attractive option for preventing the expansion of aneurysms in patients without causing 
systemic side effects. 
In conclusion, we demonstrate that targeted delivery of very small doses of MMP 
inhibitor BB-94 by NPs is an effective way to suppress MMP activity and aneurysmal 








TARGETED THERAPY WITH NANOPARTICLE LOADED WITH 
PENTAGALLOYL GLUCOSE (PGG) PROTECTS VASCULAR  
ELASTIC LAMINA FROM MMP-MEDIATED DEGRADATION  
AND PREVENTS PROGRESSION OF ABDOMINAL  







It has been established that elastin degradation is a primary cause of AAA171, and 
whether AAA is large or small, regression of it and restoration of normal arterial 
architecture would be preferable.  Although no one previously could show elastin 
regeneration, our group demonstrated the protective effect of PGG in terms of protecting 
damaged and non-damaged elastin from protease degradation and the ability of PGG to 
help tropoelastin molecules to assemble and make new crosslinked elastin by vascular 
smooth muscle cells121.  We have already developed NPs that target to AAA.  We would 
like to use these NPs to deliver PGG at the site of aneurysms.  Such site-specific targeting 
of PGG would help arterial elastin restoration.  With the regeneration of elastin, we can 




Degeneration of elastin plays a vital role in the pathology and progression of 
abdominal aortic aneurysm (AAA), a disease that is characterized by damage to the 
arterial wall.  Our previous study showed that pentagalloyl glucose (PGG), a core 




animal model when applied locally.  In this study, we tested whether targeted 
nanoparticles (NPs) can deliver PGG to the site of an aneurysm and prevent aneurysmal 
growth by protecting elastin. 
 
Approach and Results 
 
PGG-loaded albumin NPs with a surface-conjugated elastin-specific antibody 
were prepared and characterized by size, surface charge, PGG release, cellular toxicity, 
and uptake.  Aneurysms were induced by calcium chloride-mediated injury to the 
abdominal aorta in rats.  NPs were injected into the tail vein after 10 days of CaCl2-
injury.  Rats were euthanized after 38 days, and aneurysmal development was studied.  
PGG-loaded NPs were non-toxic and were not taken up by vascular smooth muscle cells, 
macrophages, or endothelial cells in vitro.  NPs with a surface tethered elastin antibody 
targeted and delivered PGG to the aneurysmal site.  Such PGG delivery led to reduction 
in macrophage recruitment, matrix metalloproteinase (MMP) activity, elastin 
degradation, calcification, and development of aortic aneurysm as compared to control 




Targeted delivery of PGG protects aortic elastin from further degradation in 
aneurysm-prone arterial segments.  It offers the potential for the development of effective 









Abdominal aortic aneurysm (AAA) is a vascular disease characterized by the 
expansion of the abdominal aorta due to structural weakening of the aortic wall.  Five-to-
nine percent (5-9%) of people over 65 years of age suffer from AAA; the mortality rate 
for ruptured AAAs is 90%.195  The cause of AAA is unknown in the majority of cases; 
however, the key regulators involved in the pathogenesis of this disease are known.  
Animal studies show the possible efficacy of medications like statins, RAS inhibitors, 
beta adrenoceptor blockers, nonsteroidal anti-inflammatory medications, and macrolides 
in the treatment of AAA, but relevant clinical studies are limited196.  Extracellular matrix 
(ECM) degradation of the wall of the aorta is a key contributor to the progression of the 
disease 197.  Matrix metalloproteinases (MMPs) are enzymes that are responsible for the 
degradation of ECM components.  As inflammation progresses, infiltrating cells secrete 
pro-MMPs, which are activated extracellularly and degrade the ECM, specifically elastin 
laminae198.  Thus, one approach to mitigate the progression of AAA is to treat the injury 
site with MMP inhibitors, such as hydroxyamate-based MMP inhibitors like 
batimastat103, marimastat199, and prinomastat97.  Our group has previously shown a 
significant reduction in the development of AAA with the targeted delivery of batimastat, 
a hydroxyamate-based MMP inhibitor200.  However, enzyme inhibitors can only stop 
further degradation but cannot reverse the disease. 
To completely restore the structural integrity of the aortic wall, it is necessary not 
only to prevent degradation, but to also allow for regeneration of the elastic lamina.  In 




glucose (PGG), has the ability to prevent elastolytic degradation by binding to enzyme 
cleavage sites on elastin.  This high affinity of PGG to elastin allows PGG to form a 
protective coating that prevents further degradation14.  We showed that a single 
periadventitial administration of PGG prior to CaCl2 injury in rats prevented degradation 
of elastin and hindered AAA development.  Recently, we have shown that PGG 
significantly increased insoluble elastin in rat aortic smooth muscle cells (RASMCs) 
from both healthy and aneurysmal aortae121.    
In this study, we tested the hypothesis that PGG-loaded bovine serum albumin 
(BSA) NPs with a surface conjugated elastin antibody will allow for the targeted delivery 
of PGG to the site of aortic aneurysm in a CaCl2 mediated injury model.  We show that 
such systemic therapy both specifically targets the aneurysmal site while sparing the 
healthy aorta and delivers PGG to the site.  This local release of PGG provides a 
protective barrier for elastin from degradation in early stage aneurysm.  We further show 
that such NP therapy allows regeneration of the damaged elastic lamina and significantly 
suppresses aneurysmal expansion of the aorta.  
 
Materials and Methods 
 
PGG-Loaded NPs Preparation 
 
Bovine serum albumin (BSA) NPs were prepared by coacervation201. 
Nanoparticles (NPs) were obtained by dissolving 250 mg of BSA (Seracare, MA, U.S.A.) 
in 4 mL of deionized (DI) water.  Pentagalloyl glucose (PGG, 125 mg) was dissolved in 
400 µl of dimethyl sulfoxide and added slowly to the BSA solution.  After an hour of 




sonication (Omni Ruptor 400 Ultrasonic Homogenizer, Omni International Inc, 
Kennesaw, GA) for half an hour.  Glutaraldehyde (EM grade 70%, EMS, PA, USA) was 
added during stirring at different concentrations of 0.3, 0.7, 1, 12, and 100 μg/mg protein 
(BSA).  These batches are named 0.3, 0.7, 1 and 12 hereafter. 
 
DIR Loaded NPs Fabrication 
 
Nanoparticles (NPs) were obtained by dissolving 250 mg of bovine serum 
albumin (BSA; Seracare, MA, U.S.A.) in 4 mL of deionized water.  2.5 mg of fluorescent 
dye, 1, 1-dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide (DIR) was 
dissolved in 100 µl of acetone and added later to the BSA solution.  After an hour of 
stirring, the mixture was added dropwise to 24 ml of ethanol under continuous sonication 
(Omni Ruptor 400 Ultrasonic Homogenizer, Omni International Inc., Kennesaw, GA) for 
half an hour.  For crosslinking, glutaraldehyde (EM grade 70%, EMS, PA, U.S.A.) was 
added during.  For animal studies to get the highest loading, 42 µg glutaraldehyde per mg 
BSA was used.  For in vitro studies, different recipes were followed.  For normal 
negatively charged ~200 nm sized particles, 12 µg glutaraldehyde per mg BSA was used 
and nanoparticles were conjugated as will be described in the next section.  For positively 
charged ~200 nm sized particles, 12 µg glutaraldehyde per mg BSA was used.  For 
negatively charged ~50 nm sized particles, 6 µg glutaraldehyde per mg BSA was used 







Conjugation of Elastin Antibody to NPs 
 
Ten milligrams (10 mg) of pentagalloyl glucose (PGG)/DIR loaded NPs were 
incubated with 2.5 mg heterobifunctional crosslinker α-maleimide-ω-N-
hydroxysuccinimide ester poly (ethylene glycol) (Maleimide-PEG-NHS ester, MW 2000 
Da, Nanocs Inc., NY, U.S.A.) to achieve a sulfhydryl-reactive particle system.  Traut’s 
reagent (34 µg, G-Biosciences, Saint Louis, MO) was used for thiolation of 10 µg of 
rabbit anti-rat elastin antibody (United States Biological, Swampscott, MA), and the 
mixture was incubated in HEPES buffer (20 mM, pH=9.0) for an hour at room 
temperature.  Thiolated antibodies were rinsed with HEPES buffer and were added to 




To quantify the NP yield, the total final dry weight of the NPs was recorded, and 




Characterization of PGG Loaded Albumin NPs— 
Particle Size, Zeta Potential  
 
Particle size and zeta potential of the NPs in suspension were determined using a 
90Plus Particle Size Analyzer (Brookhaven Instruments Co., Holtsville, NY).  
Loading efficiency of PGG in the NPs was quantified by determining PGG 
concentration in the washed out ethanol at λ (max) = 765 nm using UV 





In vitro Release Studies 
Release kinetics was determined by suspending a known amount of NPs in 
phosphate buffered saline at 37°C on a shaker.  Suspensions were centrifuged for 15 
minutes at 4000×g at room temperature for various periods of time.  The supernatant was 
collected and analyzed for PGG concentration by the addition ferric chloride, which 
binds to PGG, and the absorbance was read at 765 nm with a spectrophotometer.  Percent 




In vitro Cytotoxicity of PGG Loaded NPs  
 
Rat aortic smooth muscle cells, rat aortic endothelial cells and rat bone marrow 
macrophage cells (Cell Biologics, Inc., RA-6030F) were cultured and then incubated with 
NPs for blank (0.5 mg/ml) and PGG-NPs (0.5 mg/ml) for 24 hours.  A Live/Dead assay 
(Life Technologies, Inc., MD, U.S.A.) was performed according to the manufacturer’s 
protocol to confirm cell viability.  Cell number was calculated from the activity of lactate 
dehydrogenase (LDH) using CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega). 
 
Macrophage Uptake of NPs  
 
Elastin-antibody conjugated NPs were loaded with the fluorescent dye, DIR (EL-
NP-DIR), as described above.  Macrophages (RAW 264.7, ATCC® TIB-71™) were 
grown in 24-well tissue culture plates and subsequently incubated with EL-NP-DIR (1 




phosphate buffered saline for a total of three washes.  Cells were imaged before and after 
the washing step using the EVOS® XL Cell Imaging System to determine NP uptake.  
Two different batches of NPs were prepared as controls for charge and particle size.  One 
batch was prepared with a positive surface charge, and another batch was prepared with a 
smaller particle size as described in DIR loaded NPs fabrication section.  Positive surface 
charge was created by coating the NPs with deacetylated low molecular weight chitosan2 
(Sigma, St. Louis, MO).  Normal NPs were conjugated with elastin antibody while we 
didn’t conjugate other two batches. 
 
In vivo Study—Early Stage Aneurysm  
 
The rat abdominal aortic section (infrarenal) was subjected to perivascular 
application of calcium chloride to induce local elastin degradation200.  
Briefly, male Sprague-Dawley rats (5-6 weeks old) (n=24) were placed under 
general anesthesia by inhalation of 2% to 3% isoflurane.  Calcium chloride was applied 
periadventitially by placing a 0.50 mol/L CaCl2-soaked sterile cotton gauze pad on the 
infra-renal abdominal aorta for 15 minutes.  Afterwards, warm saline was used to flush 
the area, and sutures were used to close the incision.  Animals were given a normal diet 
for ten days.  Three animals were euthanized to study histological Changes after ten days.  
NPs loaded with PGG and conjugated with an elastin antibody (EL-NP-PGG, ~10mg/kg 
body wt.) were suspended in 200 μl of phosphate buffered saline and injected into rats 
(n=6) through the tail vein once every two weeks for a total of four weeks (2 injections 
total).  Control animals received elastin antibody-conjugated blank NPs (EL-NP-Blank) 




dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide (DIR) dye-loaded NPs (EL-
NP-DIR) to study the delivery of the NPs to the abdominal aorta through in vivo imaging.  
From these nine rats, three were euthanized one week after the first injection; the other 
three were euthanized two weeks after the first injection.  The last three received one 
extra injection in week two for a total of two injections, and these rats were euthanized 
after four weeks.  After euthanizing rats, the whole body and the individual organs were 
imaged using a Caliper IVIS Lumina XR (Hopkinton, MA) with Ex/Em of 745/795 nm, 
to calculate the biodistribution and targeting of the NPs to the site of injury in the aorta.  
Biodistribution was calculated based on the equation below: 
 
 
Rats from the EL-NP-Blank and EL-NP-PGG groups were euthanized on day 38, 
and tissues were harvested and snap frozen or formalin fixed for further analysis.  
 
Ultrasound Analyses of the Abdominal Aorta 
 
A high-frequency ultrasound device (Vevo 2100, VisualSonics, Toronto, Canada) 
utilizing a linear array probe (MS 400D, frequency 30–55 MHz) was used to complete 
ultrasound imaging of the abdominal aorta.  During the imaging, the animals were kept 
under light anesthesia by inhalation of 2% isoflurane, and fixed in the dorsal position on 
the imaging table.  Vevo 2100 analysis software was used to process M-Mode ultrasound 
data.  Three different cardiac heart beats were recorded for each M-Mode measurement 




calculate the circumferential cyclic Green-Lagrange strain with the assumption that strain 
is uniform around the vessel according to the following equation:  
 
 
Where, Dsys = Systolic internal diameter and Ddia = Diastolic internal diameter 
 
Measurement of Matrix Metalloproteinase (MMP) Activity  
in the Aorta and In Situ Zymography  
 
Aortic tissues frozen in liquid-nitrogen were pulverized and homogenized in 
RIPA extraction buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 1% Sodium deoxycholate, 0.1% SDS, with protease inhibitor cocktail) 
(Roche Diagnostic GmbH, Germany) in accordance with the manufacturer’s protocol to 
extract protein from the aortic tissues.  The total protein from the explanted aortic tissue 
after 38 days was quantified using the BCA protein assay (Pierce, IL). MMP-2 and 
MMP-9 activity were measured using an internally quenched peptide substrate (excitation 
280 nm, emission 360 nm, MMP Substrate III, Anaspec, CA).  One mg of the substrate 
was dissolved in 50 µL of dimethyl sulfoxide, and the solution was diluted in 10 mL of 
development buffer (50 mM Tris Base, 5 mM CaCl22H2O, 200 mM NaCl, 0.02% brij 
35). 2 µL of substrate stock solution and 2 µL of the extracted protein were mixed with 
96 µL of the development buffer and incubated for one hour at 37°C.  A fluorescent plate 
reader was used to read endpoint florescence intensity.  
To examine the activity of MMPs in the aortic tissue samples in situ zymography 
was performed on frozen sections.  Gelatinolytic activity was demonstrated in frozen 




sections of abdominal aorta were air-dried for 10 minutes at 4°C.  One part DQ-gelatin (1 
mg/ml of DI water) was mixed with nine parts 1% agarose (Promega, WI) in phosphate 
buffered saline containing DAPI (1 μg/ml) (Life Technologies, IL).  A drop of the 
mixture was added to each section and incubated in development buffer for one hour at 
37 C.  As a positive control, in one sample MMP activity was blocked by MMP 
inhibitor 1, 10-phenanthroline monohydrate (0.2mmol/L) (Life Technologies, OR). 
Images were captured using the EVOS® XL cell imaging system. 
 
Desmosine Content  
 
The snap frozen samples of rat aortas (abdominal) were pulverized, lyophilized, 
and hydrolyzed in 6N HCl at 95C for 12 h.  The samples were dried under a continuous 
stream of nitrogen gas (~45 minutes) and subsequently reconstituted in 1.0 mL of 0.01 N 
HCl.  The desmosine content was measured using an Enzyme Linked Immunosorbent 
Assay kit (MyBioSource, San Diego, U.S.A., catalog number MBS748709) according to 
the manufacturer’s protocol.  For comparison, three healthy abdominal aortas (non-
injured) were studied for desmosine content. 
 
Lysyl Oxidase (LOX) Activity Assay  
 
Aortic tissue snap frozen in liquid nitrogen was pulverized and homogenized in 
500 µl of 6 M urea, 50 mM Tris (pH 7.4), 1 mM PMSF Protease Inhibitor, 1 µM 
pepstatin A, and 6 µM leupeptin.  The homogenates were shaken on a plate shaker at 4°C 
overnight.  The homogenized tissues were then centrifuged at 10,000g for 30 min at 4°C.  




again.  The supernatant was collected, and LOX activity was measured by quantifying 
LOX concentration using the Amplite Fluorimetric LOX Assay Kit (AAT Bioquest, 
Sunnyvale, CA, U.S.A., catalog number 15255)202. 
 
Aneurysmal Development  
 
Initial external diameter was measured at the time of CaCl2 injury.  Final aortic 
diameter was recorded before euthanasia on day 38.  Aneurysmal development was 
calculated as mentioned before. 
 
Histological Analysis  
 
Formalin-fixed samples were embedded in paraffin, and 5 µm sections were made 
and mounted on glass slides.  The slides were heated overnight 55-60°C to adhere the 
tissues to the slides and melt the paraffin.  Subsequently, the slides were deparaffinized 
with xylenes and graded ethanol and stained with Verhoeff-van Gieson (VVG) staining 
for elastic fibers, Alizarin Red S staining with a Light Green SF counterstain for 
calcification, hematoxylin and eosin staining for tissue morphology, and phenol staining 
for PGG. 
 
Immunostaining for Macrophages (CD68) 
 
Tissues preserved with formalin were embedded in paraffin and sectioned as 
previously described.  Subsequently, the slides were deparaffinized with xylenes and 
graded ethanol, and antigen retrieval was done using citrate buffer (Millipore, MA, 
Catalog number 21545).  The slides were incubated overnight at 4°C with the primary 




was completed using a DAB kit (Enzo Life Sciences, NY, Catalog number ADI-950-122-
0100). 
 
Immunofluorescence for PECAM-1 (CD31) 
 
Tissues from DIR rats preserved with formalin were embedded in paraffin and 
sectioned as previously described.  Subsequently, the slides were deparaffinized with 
xylenes and graded ethanol, and antigen retrieval was done using citrate buffer 
(Millipore, MA, Catalog number 21545).  The slides were incubated overnight at 4°C 
with the primary antibody, Rabbit Anti Rat CD31 (Novus Biologicals, Catalog number, 
Nb100-2284).  Staining was completed using TRITC conjugated goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratory, Catalog number 111-025-003). 
 
Alanine Aminotransferase (ALT) Analysis 
 
Blood was drawn via a heart stick with a 3 mL syringe, and the blood was 
centrifuged at 3000 rpm for 3 min.  The serum was examined for the activity of Alanine 
Aminotransferase (ALT) using a commercially available kit (Sigma, St. Louis, MO, 
Catalog number, MAK052). 
 
Histological Analysis of Liver 
 
Formalin-fixed samples were embedded in paraffin, and 5 µm sections were 
mounted on glass slides and heated overnight to adhere the tissues to the slides and melt 
the paraffin.  Subsequently, the slides were deparaffinized with xylenes and graded 







Data were analyzed by one-way ANOVA followed by Tukey’s test or Dunnett’s 
test.  Levene's test was used to verify the homogeneity of variances and normality 
assumption was checked using a Shapiro-Wilk test.  Dunnett's procedure was used when 
comparing all other treatments to a reference and Tukey's was used for all pairwise 
comparison.  
Exact permutation test was performed using the NPAR1WAY procedure in SAS.  
The data are expressed as the mean ± standard deviation; results were considered to be 




Nanoparticle Yield and Loading  
 
BSA NPs were prepared with the coacervation method.  The batch with 12 µg 
glutaraldehyde/mg BSA had the best yield (~61%), which was significantly higher than 
the yield for other batches (See Figure 23A).  The batch with 12 µg glutaraldehyde/mg 
BSA also showed good PGG loading as compared to the other batches (See Figure 23B).  
 
Particle Size and ζ-Potential 
 
NP size increased with increasing glutaraldehyde concentration during NP 
preparation. Increased size led to a decrease in ζ-potential; however, all NPs showed 







Figure 23.  Yield and Loading of NPs with 0.3, .7, 1 and 12 µg glutaraldehyde per mg of 







Figure 24.  Zeta potential and particle size of NPs with 0.3, 0.7, 1 and 12 µg 






In vitro PGG Release from Nanoparticles 
 
The PGG was released within 10 days with significant burst release in the first 
few hours from all batches of NPs except the batch in which 12 µg glutaraldehyde/mg 
BSA was added during sonication.  This particular batch showed more controlled release 
of PGG that lasted for 60 days (See Figure 25); thus, these NPs were chosen for further 
studies.  
 
In vitro Cytotoxicity and Macrophage Uptake  
 
The rat aortic smooth muscle cell (RASMCs), the rat aortic endothelial cell 
(RAOEC), and the rat bone marrow macrophage (BMM) viability as assessed by live-
dead assays showed no significant change after 24 hours of incubation with NPs in 
comparison to the control (See Figure 26).  
No significant changes were observed in number of cells based on LDH assay 
(See Figure 27). 
Because many macrophages are present at the AAA site, we assessed macrophage 
uptake of NPs in vitro.  NPs loaded with 1, 1-dioctadecyl-3, 3, 3, 3-
tetramethylindotricarbocyanine iodide (DIR) dye (ζ-potential~ -31, size~ 200 nm) were 
incubated with cells for 24 hours.  Macrophage uptake was not detected due to the 
negative charge and optimum size of the NPs (See Figure 28, I and II).  When the 
surface-charge was changed to be positive with the addition of chitosan, (ζ-potential: 
+13, size~ 200 nm) or when NPs were smaller (ζ-potential: -37, size~ 50 nm), NPs were 































used NPs with negative surface charge and ~200 nm particle size for animal studies 
because they were resistant to macrophage uptake.  
 
Biodistribution of NPs 
 
We used a calcium chloride-mediated acute perivascular injury model to cause 
elastin degradation and aneurysmal expansion in the infrarenal abdominal aorta of rats.  
Ten days after injury, DIR dye-loaded NPs were systemically administered via tail vein 
injection.  The NPs targeted the injured aortic elastic lamina sites within the first few 
hours and were retained even after one week as measured by fluorescence intensity 
(IVIS, 59±8% targeting based on per weight basis).  NPs remained at the site of elastin 
damage in the aorta after two weeks with no additional injections, although the amount of 
NPs decreased (36±5%).  With the addition of another injection at two weeks, targeting 
to the damaged aorta was restored to 67±13% when tested at four weeks, suggesting that 
one injection every two weeks can successfully keep NP targeting at a high level (See 
Figure 29). 
The fluorescence signal of DIR (% florescence/dry weight of organ) after 4 weeks 
decreased from 5.6% to 4.7% for the kidneys, from 2.6 to 1.6% for the liver, and from 30 
to 20% for the spleen in comparison to the fluorescence observed after 1 week (See 
Figure 30).  These results show that NPs accumulated at the injury site, while other 
organs were clearing non-targeted NPs.  
More significantly, infiltration of the NPs was seen from the vasa vasorum on the 
adventitial side rather than from the luminal side (See Figure 31A) while nanoparticle did 













Figure 30.  Organ distribution of fluorescent NPs after one, two, and four weeks. (#P < 










Histological Analysis of the Abdominal Aorta  
 
Histological sections of aortae 10 days post calcium chloride injury showed 
elastin damage (See Figure 32). 
After confirming elastin damage 10 days post injury, in order to study the effect 
of targeted delivery of PGG, we systemically injected either EL-NP-PGG or EL-NP-
Blank (control without PGG) NPs ten days after CaCl2 injury once every two weeks.  
Hematoxylin and eosin staining showed significant inflammation in the adventitia in the 
EL-NP-Blank group with a degraded medial layer (See Figure 33A), while the EL-NP-
PGG group maintained greater structural integrity and had little inflammation after 38 
days (See Figure 33B).  Verhoeff-van Gieson (VVG) staining revealed that the elastic 

















the elastic lamina was preserved in the EL-NP-PGG group (See Figure 33D).  Alizarin 
Red-S staining showed heavy medial calcification in the EL-NP-Blank group (See Figure 
33E), and a substantial reduction in calcification in the EL-NP-PGG group (See Figure 
33F).  For histological confirmation of PGG delivery by the NPs, aortic tissues were 
stained with a phenol-specific stain.  Only the EL-NP-PGG group showed phenol specific 
staining surrounding the elastic lamina (See Figure 33H), while the EL-NP-Blank group 
showed no phenolic staining (See Figure 33G), clearly suggesting that NPs delivered 
PGG to the aneurysmal site.  Macrophage immunohistochemistry showed pan-
macrophage marker (CD68) in EL-NP-Blank group adventitia (See Figure 33I1-4) while 
EL-NP-PGG group doesn’t show CD68 (See Figure 33J1-4).  
Moreover, full aortic sections were shown in all six rats of each group (See Figure 
34). 
 
Circumferential Strain Assessment with  
High-Frequency Ultrasound 
 
Circumferential strain for young healthy rats before calcium chloride injury was 
12.25±1.28% (See Figure 35A).  It was reduced to 3.27±2.7% for the EL-NP-Blank 
group at 38 days after injury suggesting stiffening of the aorta (See Figure 35B).  
Circumferential strain for the EL-NP-PGG group was similar to the healthy control 
11.93±1.38% after 38 days, clearly suggesting that PGG maintained healthy elastic 















Figure 35.  M-mode tracings and circumferential cyclic strain over 38 days. 
 
 
MMP Activity  
 
We next examined if NPs loaded with PGG inhibited local MMP activity at the 
site of AAA. Snap frozen tissues were collected, and MMP activity was measured with a 
MMP fluorogenic substrate assay.  When normalized to total protein content and reported 




a 250% increase in MMPs as compared to the healthy thoracic aorta.  In the EL-NP-PGG 
group, MMP activity was suppressed to healthy levels (See Figure 36A).  This result was 
further confirmed by in situ zymography for MMPs where high activity was seen in the 
EL-NP-Blank group, while minimal MMP activity was seen in EL-NP-PGG group (See 
Figure 36A B).  
 
Elastin Remodeling at the Aneurysm Site 
 
Lysyl Oxidase (LOX) activity assay:  When blank NPs were delivered (EL-NP-
Blank), lysyl oxidase (LOX) activity in the abdominal aorta was reduced to 50% of the 
healthy thoracic aorta, showing suppression of elastin remodeling.  When PGG loaded 
NPs were delivered (EL-NP-PGG), there was a 250% increase in LOX activity as 
compared to the healthy thoracic aorta (See Figure 37), confirming that PGG supports 
LOX production at the aneurysm site. 
Desmosine content (characteristic of elastin crosslinking):  Healthy non-injured 
abdominal aortas had 1606±173 pmole desmosine per mg dry tissue.  Desmosine content 
of the aortic samples showed a significant decrease in the EL-NP-Blank group (446±110 
pmole/mg dry tissue), showing degradation of elastic fibers.  In contrast, the EL-NP-PGG 
group showed restoration of healthy desmosine levels (1405±328 pmole/per mg dry 




The control group (EL-NP-Blank) showed an increase in aortic diameter 






Figure 36.  MMP activity (-2 and -9) by fluorogenic substrate and in situ zymography. * 














did not have any therapeutic effect on aneurysmal development.  However, when PGG-
loaded NPs were injected, a significant suppression of aneurysmal development was seen 
(3 fold) (p-value <0.05, using exact permutation test) (See Figure 39). 
 
Hepato-Toxicity of NPs 
 
PGG exposure had minimal cytotoxic effects in rats.  Noticeable changes 
indicative of hepatotoxicity were not observed in hematoxylin and eosin stained sections 
of liver (See Figure 40).  In addition, the levels of serum alanine aminotransferase (ALT), 
an enzyme used to assess liver function, were consistently within the acceptable range of 
5 to 45 U/L (EL-NP-Blank rats, 13±0.7 U/L, and EL-NP-PGG rats, 17.8±0.9 U/L), and 
these results are comparable with previous studies14. 
 
Elastin Remodeling at the Aneurysm Site for BB-94 NPs Group  
 
In the previous chapter, we investigated the treatment of AAA using BB-94 
loaded nanoparticles.  To compare PGG and Bb-94 we measure LOX and desmosine for 
those samples from previous study.  While batimastat reduced the MMP activity, it was 
only slightly effective in increasing the desmosine content of the aorta, (851±192 pmole 
desmosine per mg dry weight of tissue) (See Figure 41). 




This study demonstrates that the use of targeted NPs carrying PGG, a potent 
protector of elastin, can successfully inhibit the progression of AAA, and that such 






Figure 39.  Expansion of external diameter in two groups after 38 days. #, P < 0.05, Exact 




















Figure 41.  Desmosine content of EL-NP-Blank group vs EL-NP-BB94 group. 








Figure 42.  Analysis for LOX content of EL-NP-Blank group vs EL-NP-BB94 group. 
 
 
We first optimized NP size, surface charge, and PGG loading by varying the 
amount of crosslinker during NP fabrication.  The particle size, loading, and yield 
increased with increasing glutaraldehyde concentration, which is similar to what has been 
reported earlier_.  When 12 µg glutaraldehyde/ mg BSA was used, we obtained NPs (ζ-
potential~ -20mV, size ~200 nm) optimal for targeting the ECM in aortic aneurysm 
according to previously reported values 167.  Also, as reported previously203, the amount 
of glutaraldehyde cross linking is a crucial parameter for drug release from the NPs.  We 
found that the 12 µg glutaraldehyde/mg BSA batch had the longest release profile for 
PGG.  Thus, these were chosen for further in vivo studies.  
We wanted our NPs to target the degraded elastic lamina present in the ECM and 
not be removed by phagocytosis by resident macrophages.  Macrophages are present at 




uptake by macrophages.  To confirm the mechanisms of uptake, we also made the same 
size NPs but with a positive surface charge or smaller NPs with negatively charged 
surfaces.  Both were taken up by macrophages in vitro.  This data clearly suggests that 
both size (~200 nm) and negative surface charge were responsible for minimizing uptake 
by macrophages.  However, the in vitro results show minimal uptake but the mechanism 
of targeting can be a combination of both macrophages uptake and anti-elastin/elastin 
attachment in vivo.  
Biodistribution data showed that NPs clearance occurs in spleen and liver as it 
was shown before205.  It is possible that nanoparticles, are taken up primarily by Kupffer 
cells in the liver. 
Phenol staining of histological sections clearly showed that PGG was indeed 
released at the aneurysmal site by targeted NPs, and it bound to elastin and protected it 
from further damage, as the aorta appeared healthy and the elastic lamina was preserved 
in the PGG group as compared to the blank NP group.  Considering the loading, burst 
release of nanoparticles and targeting, 80 µg PGG will be released in first 5 hours that is 
enough to preserve elastin fibers.  
Local inflammatory cells and vascular smooth muscle cells secrete MMPs in 
aneurysmal tissue3.  MMP-9 and -2 play significant roles in AAA development as it has 
been shown that MMP-9 and -2 knockout mice are protected from aneurysm formation 
and progression206.  The goal of targeted treatment is either to suppress MMP activity at 
the site of AAA or to protect elastin fibers from further degradation by blocking sites on 




tightly to elastic lamina and prevents its degradation by MMPs14.  In situ zymography 
showed that the MMP activity was significantly suppressed in the EL-NP-PGG group as 
compared to the EL-NP-Blank group.  This may be because PGG binding to elastin 
caused inhibition of elastin degradation and release of elastin peptides.  It is known that 
elastin peptides are chemotactic to macrophages207.  We also saw decreased macrophage 
response at the aneurysm site that may be the cause of lower MMP activity seen in the 
PGG group.  This suggests that PGG protects elastin, and less elastin peptides are present 
in the EL-NP-PGG group.  Therefore, elastin-derived peptide-mediated inflammatory cell 
recruitment is reduced208.  However, we have looked at CD68, but more studies are 
needed to quantify M1 and M2 macrophages population.  
Histological analysis of aortae showed inflammatory thickening of the aneurysm 
wall 209 that is an indicator of inflammatory AAA while EL-NP-PGG group did not show 
inflammation. 
It has been shown in human AAA samples that desmosine content is significantly 
reduced in aneurysm samples in comparison to healthy aortic samples210, which is what 
we have also observed in this study.  Clearly, CaCl2 mediated injury caused elastin 
degradation as seen by histology and significantly lower desmosine content (446±110 
pmole/mg dry tissue), an elastin-specific cross-linking amino acid, in the blank NP group.  
The EL-NP-PGG group showed intact elastic lamina by histology and desmosine content 
similar to that of the healthy uninjured abdominal aorta (1405±328 pmole /per mg dry 
tissue for the EL-NP-PGG group and 1606±173 pmole desmosine per mg dry tissue for 




lower inflammation and MMP activity or if there was active elastic fiber remodeling by 
VSMCs in the PGG group.  We have previously shown that the MMP inhibitor 
batimastat also prevents aneurysm expansion200.  While batimastat reduced MMP 
activity, it was only slightly effective in increasing the desmosine content of the aorta, 
(851±192 pmole desmosine per mg dry weight of tissue).  PGG delivery remarkably 
allowed for the preservation of desmosine content similar to the healthy aorta despite 
aortic injury induced by calcium chloride 10 days prior to NP delivery.  
To further test why PGG delivery caused restoration of healthy elastic lamina, we 
chose to study the activity of LOX.  LOX is an extracellular copper-containing enzyme 
that catalyzes the formation of aldehydes from lysine residues in elastin precursors, 
resulting in cross-linking of elastin, which is essential for the integrity and elasticity of 
mature elastin211.  In our study, tissues from the EL-NP-PGG group showed 150% 
increase in the production of LOX, which was significantly lower in the abdominal tissue 
of the EL-NP-Blank group.  On the other hand, batimastat delivery did not result in a 
difference in LOX activity.  This increased LOX production at the AAA site only in the 
PGG group would lead to crosslinking of tropoelastin molecules secreted by cells and 
may have allowed for the creation of healthier elastic lamina.  This was evident in 
histological sections only from the PGG group.  We have also shown previously that 
LOX production increases when aneurysmal vascular smooth muscle cells are treated 
with PGG in vitro and that in turn increased insoluble elastin production by cells121.  This 
observation was confirmed in vivo in the present study.  Although the exact mechanism 




polyphenols like PGG lock in soluble tropoelastin molecules secreted by cells in the 
extracellular matrix.  This then signals cells to produce more LOX to crosslink this 
tropoelastin and create elastic fibers.  We have also shown that fibrillin levels increase in 
vivo when cells are treated with PGG.  Fibrillin is an essential glycoprotein found at the 
periphery of mature elastic fibers212.  Others have shown that LOX gene transfer resulted 
in partial prevention of the development of CaCl2-induced AAA213.  Thus, PGG works 
by dual action.  It binds to degraded elastic fibers and protects it from further degradation 
(stabilization), but at the same time it locks in tropoelastin secreted by cells to regenerate 
lost elastic lamina (regeneration).  With targeted delivery of PGG, the protection of 
elastin from further damage and ongoing elastin regeneration leads to suppression of 
aneurysmal development in the aorta as shown by lower aneurysmal expansion in the EL-
NP-PGG group (57% expansion) compared to the EL-NP-Blank group (158% 
expansion). 
Finally, we also show that the NPs and PGG delivery were not hepato-toxic.  ALT 
is released into the blood due to the loss of liver cells.  Therefore, an increase in this 
enzyme is a sign of liver cell damage214.  ALT levels were not altered by NP injection, 
and the livers appeared to be normal in histological stainig, suggesting that NPs are not 
toxic to the liver in this 38 day study.  
In conclusion, we show that targeted delivery of PGG by NPs is an effective way 
to protect elastin fibers against further damage and restore healthy elastic lamina in an 
experimental rat model of AAA.  Thus, such targeted PGG therapy leads to suppression 






REVERSAL OF ELASTIN CALCIFICATION AND ANEURYSM IN A  
RAT MODEL USING DUAL TARGETED THERAPY WITH  





Degeneration of elastin plays a crucial role in the pathology and progression of 
abdominal aortic aneurysms (AAA), a disease characterized by the loss of structural 
integrity of the arterial wall.  AAA is often associated with calcification, which increases 
the risk of AAA rupture4.  Current option for AAA is the replacement of weakened aorta 
with a vascular graft.  Our group has shown earlier that treatment with pentagalloyl 
glucose (PGG) increased elastin matrix deposition by healthy and aneurysmal vascular 
smooth muscle cells in vitro121.  Furthermore, we have shown that EDTA nanoparticles 
can remove calcification from calcified artery with minimal dose of EDTA using the 
same nanoparticles technology172.  We would like to use EDTA and PGG and deliver it at 
the site of aneurysms.  Such dual therapy of EDTA followed by PGG help reducing 




Our previous study showed that EDTA loaded nanoparticles (NPs) conjugated 
with an anti-elastin antibody can be targeted to the site of calcification in a calcium 
chloride rat model.  Here, we tested whether EDTA NPs can first remove calcification 





Approach and Results 
 
Albumin nanoparticles (NPs) with surface conjugated elastin-specific antibody 
that targets only degraded elastic lamina and loaded with either EDTA or PGG were 
prepared.  The calcium chloride induced rat model of abdominal aortic aneurysm was 
used.  The animals were divided into four groups.  A moderate stage aneurysm and 
calcification was allowed to develop for four weeks and one group of animals received 
tail vein injection of EDTA NPs (twice a week).  Two weeks after EDTA therapy (total 6 
weeks), these rats received PGG loaded NPs (once every two weeks).  In other three 
groups, aneurysm was allowed to progress for six weeks.  At that point, one group 
received blank NPs, and one group received PGG NPs (once every two weeks).  As a 
control, one group received an MMP inhibitor, BB-94 loaded NPs (once a week).  After 
12 weeks, the rats were euthanized, and disease development, calcification, and elastic 
lamina restoration was studied.  EDTA followed by PGG NP delivery lead to reduction in 
macrophage recruitment, MMP activity, elastin degradation and calcification in the aorta 
as compared to control blank, BB-94, and PGG NPs delivery alone.  It restored vascular 





Dual targeted therapy may be an attractive option to remove mineral and restore 








Clinically, abdominal aortic aneurysms (AAAs) are characterized by chronic 
inflammation and degradation of extracellular matrix (ECM) components by proteolytic 
enzymes like matrix metalloproteinases (MMPs).  This can lead to inflammatory 
infiltration in the adventitia and calcification and degeneration of medial elastic lamina195,215.  
The infiltrating cells, including B and T cells, mast cells, macrophages, and neutrophils 
secrete proinflammatory mediators, leading to the acceleration of matrix degradation and 
causing weakening of the blood vessel wall216.  Calcification is frequently found within 
the aneurysm wall, and the calcified region has a higher stiffness than the surrounding 
arterial wall217.  Although abdominal aortic aneurysm is a life-threatening disease, there 
are no pharmacological therapies available to stop growth and reverse the disease.  
Several drug therapies in animal models have been shown to be successful in preventing 
aneurysm formation, but were started at the onset of aneurysm218.  Such studies provide 
insight into the mechanisms of aneurysm formation, but do not provide therapy for 
already developed aneurysms.  Over ninety percent of patients are diagnosed at a 
moderate stage of aneurysm, and therapies are critically needed to reverse these.  
Currently, such patients are monitored for aneurysmal expansion by ultrasound; when the 
diameter of the diseased aorta exceeds 5.5 cm surgical replacement, surgical replacement 
with a vascular graft is recommended.  This threshold is arbitrary as it has been shown 
that at that size rupture risk exceeds interventional risk but ten percent of deaths occur 




Perivascular application of calcium chloride to the infra-renal aorta of rats is a 
common model for aortic abdominal aneurysm (AAA).  It shows noticeable 
inflammatory infiltrates including macrophages and medial elastin calcification similar to 
that seen clinically67.  Our group has previously shown that systemic delivery of elastin-
antibody conjugated, poly (D,L-lactide) nanoparticles loaded with hydroxamate-based 
MMP inhibitor batimastat (BB-94) causes suppression of AAA when delivered at the 
onset of disease200.  We have also shown that EDTA-loaded bovine serum albumin 
(BSA) nanoparticles with a surface conjugated elastin antibody deliver EDTA to the 
aneurysm site and remove mineral when applied at an early stage of the disease172.  
However, both these studies were initiated at a very early stage of the disease.  To mimic 
the clinical situation and treat moderate-size aneurysms, we designed this study to test if 
targeted nanoparticles can regress already developed aneurysms in rats.  It has been 
previously shown that calcification is a sign of the inflammatory process involved with 
the degeneration of the arterial wall, and it is correlated with increased risk of aneurysm 
rupture4.  Here, we used a dual-therapy approach:  First, we employed targeted 
nanoparticle-based delivery of EDTA to removed mineral deposits in arteries.  Then, we 
targeted delivery of pentagalloyl glucose (PGG), a polyphenol known to stabilize elastin 
and increase elastic fiber deposition14.  We show that such dual therapy removes mineral 
deposits from calcified arteries and restores elastic lamina in the aneurysmal wall, leading 











 The purpose of this study was to investigate the effect of calcium removal and 
elastin preservation on calcium chloride-induced abdominal aortic aneurysm in a rat 
model.  We used anti-elastin conjugated nanoparticles loaded with DIR to target the 
injury site.  Further, we loaded the nanoparticles with either EDTA, BB-94 or PGG to see 
their therapeutic effect, if any, on AAA.  In addition to histological analysis, we 
measured diameter change, MMP activity, desmosine, LOX and calcium content to 
investigate the effect of these treatments.  Sample sizes were determined by power 
analysis using our lab’s previously published data as preliminary data.  A power analysis 
with 90% power and α = 0.05 indicated that a sample size of a minimum of six rats per 
group was required for diameter change.  Data analyses were not blinded.  Outliers were 
not excluded. 
 
Preparation of DiR-loaded, EDTA-loaded  
and PGG-loaded nanoparticles  
 
Bovine serum albumin (BSA) NPs were prepared by coacervation201.  Briefly, 
DIR-loaded nanoparticles (NPs) were obtained by dissolving 250 mg of bovine serum 
albumin (BSA; Seracare, MA) in 4 mL of deionized water.  Then, 2.5 mg of the 
fluorescent dye 1, 1-dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide (DIR) 
was dissolved in 100 µl of acetone and added to the BSA solution.  After an hour of 
stirring, the mixture was added dropwise to 24 mL of ethanol under continuous 




Kennesaw, GA) for half an hour.  For crosslinking, glutaraldehyde (EM grade 70%, 
EMS, PA) was added during stirring (42 µg per mg of BSA).  Next, 10 mg of DIR-loaded 
NPs (DIR-NPs) were incubated with 2.5 mg heterobifunctional crosslinker α-maleimide-
ω-N-hydroxysuccinimide ester poly (ethylene glycol) (Maleimide-PEG-NHS ester, MW 
2000 Da, Nanocs Inc., NY) to achieve a sulfhydryl-reactive particle system.  Traut’s 
reagent (34 µg, G-Biosciences, Saint Louis, MO) was used for thiolation of 10 µg of 
rabbit anti-rat elastin antibody (United States Biological, Swampscott, MA), and the 
mixture was incubated in HEPES buffer (20 mM, pH=9.0) for an hour at room 
temperature.  Thiolated antibodies were rinsed with HEPES buffer and were added to 
NPs (4 µg antibody per 1 mg NPs) and incubated overnight for conjugation. 
EDTA-loaded nanoparticles were obtained by dissolving 200 mg of bovine serum 
albumin (BSA; Seracare, MA) and 100 mg ethylenediaminetetraacetic acid disodium salt 
(EDTA) (Fisher scientific, NJ) in 4 mL of deionized water and pH was adjusted to 8.5.  
The aqueous solution was added drop-wise to 16 mL ethanol under probe sonication for 1 
hour.  For crosslinking, glutaraldehyde was added during sonication (10 µg per mg of 
BSA).  The elastin antibody conjugation procedure was similar to that of DiR-loaded 
NPs. 
PGG-loaded nanoparticles were obtained by dissolving 250 mg of BSA (Seracare, 
MA) in 4 mL of deionized (DI) water. Pentagalloyl glucose (PGG, 125 mg) was 
dissolved in 400 µl of dimethyl sulfoxide and added slowly to the BSA solution.  After an 
hour of stirring, the mixture was added dropwise to 24 mL of ethanol under continuous 




of 12μg/mg protein (BSA).  The elastin antibody conjugation procedure was similar to 
that of DiR-loaded NPs. 
 
In vivo Study  
 
Calcium Chloride-Injury Model 
 
Perivascular application of calcium chloride was used to create aneurysms in the 
abdominal aorta of the rats69.  By 30 days, elastic lamina showed extensive calcification 
and degradation with a moderate increase in external diameter that mimics clinically 
moderate stage of the disease.  We chose this time point to start the treatments to reverse 
AAA.  The diagram in Figure 1 depicts details of the animal experimentation.  Briefly, 
Sprague-Dawley rats (5-6-weeks-old) were placed under general anesthesia (2% to 3% 
isoflurane).  A 0.50 mol/L CaCl2-soaked sterile cotton gauze was placed on the exposed 
infrarenal abdominal aorta for 15 minutes.  Afterwards, the area was flushed with warm 
saline and sutures were used to close the abdominal incision.  After surgery, the animals 
were given a normal diet and allowed to recover for thirty days.  Either DiR dye-loaded 
or drug-loaded NPs were then introduced. 
 
Targeting and Bio-distribution of NPs 
 
Thirty days after the initial CaCl2 injury, rats were injected with elastin antibody 
conjugated and DIR dye-loaded NPs (EL-NP-DIR) via the tail vein.  After 24 hours, the 
rats were euthanized.  The entire body and the individual organs were imaged using a 




biodistribution and targeting of NPs to the site of injury in the aorta.  Biodistribution was 
calculated as mentioned before. 
 
Reversal of Moderate-Size Aneurysms with Drug Therapy 
 
Thirty days after perivascular application of calcium chloride, the rats were 
divided into four separate treatment groups (n=6 per group).  One group of rats received 
tail vein injection of NPs loaded with EDTA and conjugated with elastin antibody (EL-
NP-EDTA, ~10 mg/kg body wt.) suspended in 200 µL of PBS twice a week; the other 
three groups did not receive any treatment.  After the first two weeks, the EDTA-treated 
group was given NPs loaded with PGG and conjugated with an elastin antibody once 
every two weeks for four weeks (EL-NP-EDTA+NP-PGG ~10mg/kg body wt.).  The 
second group of six rats was given NPs loaded with PGG and conjugated elastin antibody 
(EL-NP-PGG, ~10mg/kg body wt.) once every two weeks over four weeks.  A third 
group of six rats was given NPs loaded with BB-94 and conjugated elastin antibody (EL-
NP-BB94, ~10mg/kg body wt.) once every week for four weeks.  Finally, the last group 
of six rats received blank NPs conjugated with elastin antibody once every two weeks for 
four weeks (EL-NP-Blank~10mg/kg body wt.).  Two weeks after completing treatment, 
the rats were then euthanized.  The entire study lasted for 12 weeks total.  After 
euthanasia, the tissues were harvested.  They were either snap frozen or fixed in formalin 








MMP Activity in Rat Aorta and In situ Zymography 
 
The snap frozen samples of the abdominal aorta were pulverized and 
homogenized in RIPA extraction buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% SDS, with protease inhibitor 
cocktail) (Roche Diagnostic GmbH, Germany) in accordance with the manufacturer’s 
protocol to extract protein from the aortic tissues.  A BCA protein assay (Pierce, IL) was 
used to quantify the total protein in the harvested aortic tissue.  MMP activity was 
measured with an internally quenched peptide substrate (excitation 280 nm, emission 
360nm, MMP Substrate III, Anaspec, CA).  One mg of substrate dissolved in 50 µl of 
DMSO was diluted in 10 ml of development buffer (50 mM Tris Base, 5mM 
CaCl2•2H2O, 200mM NaCl, 0.02% brij 35).  The development buffer (96 µl) was mixed 
with 2 µl of extracted protein along with 2 µl of substrate stock solution and then 
incubated for an hour at 37°C.  A fluorescence plate reader was used to read the endpoint 
florescence intensity.  
In situ zymography was performed on frozen sections to evaluate MMP activity in 
the aortic tissue samples.  Sections of the abdominal aorta obtained from sectioning with 
a cryostat (8 µm) were left to air-dry for 10 min at 4°C.  One part DQ-gelatin (1mg/ml of 
DI water) was mixed with nine parts 1% agarose (Promega, WI) in PBS containing DAPI 
(1 µg/ml) (Life Technologies, IL).  Each section was treated with a drop of the mixture 
and then incubated at 37°C for one hour in the development buffer.  MMP inhibitor 1, 
10-phenanthroline monohydrate (0.2 mmol/L) (Life Technologies, OR), was used to 




Afterwards, an EVOS® XL cell imaging system was used to capture images of the 
samples. 
 
Desmosine Content of the Aorta 
 
The snap frozen samples of the abdominal aorta were pulverized, lyophilized and 
hydrolyzed in 6N HCL at 95°C for 12 h14.  Using nitrogen gas supplied in a continuous 
stream, the samples were dried.  Afterwards, they were reconstituted in 1.0 mL of 0.01 N 
HCL. An ELISA kit (MyBioSource, San Diego, CA) was used to measure the desmosine 
content in accordance with the protocol set by the manufacturer.  Another group of six 
healthy non-injured abdominal aortas were also studied for comparison. 
 
Lysyl Oxidase (LOX) Activity Assay 
 
After being snap frozen in liquid nitrogen, the aortic tissues were pulverized and 
then homogenized in 500 µl of 6 M urea, 10mM Tris (pH 7.4), 1mM PMSF Protease 
Inhibitor, 1µM pepstatin A, and 6 µM leupeptin.  These homogenates were then placed 
on a plate shaker and shaken overnight at 4°C.  The homogenized tissues were then 
centrifuged at 10,000 g for 30 min at 4°C.  The same buffer was used again to suspend 
the pellets, which were subsequently homogenized and centrifuged.  Using the LOX 
Assay Kit (AAT Bioquest, Sunnyvale, CA) to quantify the LOX concentration in the 




Total calcium content was measured after lyophilizing.  Lyophilized tissue was 




minutes).  The tissue was subsequently reconstituted in 0.01 N HCl and samples were 
analyzed using the Spectro Acros ICP Spectrometer (SPECTRO Analytical Instruments, 
Kleve, Germany) at the Clemson University Agricultural Service Laboratory.    
 
Ultrasound Analyses of the Abdominal Aorta 
 
A high-frequency ultrasound device (Vevo 2100, VisualSonics, Toronto, Canada) 
utilizing a linear array probe (MS 400D, frequency 30–55 MHz) was used to image the 
abdominal aorta.  During imaging, the animals were kept under light anesthesia by 
inhalation of 2% isoflurane and fixed in the dorsal position on the imaging table.  
 
Circumferential Strain Assessment with High-Frequency Ultrasound 
 
Vevo 2100 analysis software was used to process M-Mode ultrasound data.  
Three different cardiac heart beats were recorded for each M-Mode measurement made.  
Systolic and diastolic diameters were measured, and this data was used to calculate the 
circumferential cyclic Green-Lagrange strain with the assumption that strain is uniform 




Aortic External Diameter Change 
 
Initial external diameter was measured at the time of the CaCl2 injury.  Final 
aortic diameter was recorded before euthanasia (12 weeks after injury).  Additionally, we 
euthanized a group of rats 30 days after injury to observe diameter change at the onset of 







Formalin-fixed samples were embedded in paraffin, and 5 µm sections were 
mounted on glass slides and heated overnight to adhere the tissues to the slides and melt 
the paraffin.  Subsequently, the slides were deparaffinized with xylenes and graded 
ethanol and stained with hematoxylin and eosin for tissue morphology, Verhoeff-van 
Gieson (VVG) for elastic fibers, phenol staining for PGG, Masson's trichrome for 
collagen and Alizarin Red S with a Light Green SF counterstain for calcification.  Liver 
samples were treated the same way and stained with hematoxylin and eosin for tissue 
morphology. 
 
Immunohistochemistry for Macrophages, Osteopontin (OPN) 
and Smooth Muscle Cells (VSMCs) 
 
Tissues preserved with formalin were embedded in paraffin and sectioned as 
previously described.  Subsequently, the slides were deparaffinized with xylenes and 
graded ethanol, and antigen retrieval was done using citrate buffer (Millipore, MA).  The 
slides were incubated overnight at 4°C with the primary antibody, Mouse Anti Rat CD68 
(Bio-Rad, Hercules, CA) or Rabbit Anti Rat Osteopontin (Rockland Immunochemical, 
PA).  Staining was completed using a DAB kit (Enzo Life Sciences, NY).  
Counterstaining followed using hematoxylin or eosin.  For VSMCs, the slides were 
incubated overnight at 4°C with the primary antibody, mouse smooth muscle actin (Santa 
Cruz Biotechnology, CA).  Staining was completed using a mouse-HRP AEC kit (Enzo 







Blood was drawn via a heart stick with a 3 mL syringe, and after allowing 30 min 
for clotting, the blood was centrifuged at 3000 rpm for 3 min.  Rat serum was examined 
for IFN-γ using a rat ELISA kit (R&D system, MN). 
 
Alanine Aminotransferase (ALT) Analysis 
 
The serum was examined for the activity of alanine aminotransferase (ALT) using 




Data were analyzed by one-way ANOVA followed by Tukey’s test.  Levene's test 
was used to verify the homogeneity of variances and normality assumption was checked 
using a Shapiro-Wilk test.  Tukey's test was used for all pairwise comparison.  
An exact permutation test was performed using the NPAR1WAY procedure in 
SAS.  The data are expressed as the mean ± standard deviation; results were considered 




Nanoparticles Delivery Design 
 
Study designed was shown in Figure 43 for targeting or therapeutic purposes. 
 
Aortic Disease Status at the Onset of Targeted Therapy 
 
Aortic aneurysm and calcification were allowed to develop for 30 days after the 






Figure 43.  Schematic representation of the experiment. 
 
 
Desmosine content of the aortas decreased from 1808±290.5 to 421.9±104 pmole/mg dry 
tissue after 30 days.  Calcium content of the aortas was 43±3 µg/mg dry weight after 30 
days.  In situ zymography on frozen sections of abdominal aorta from 30 days after 
surgery showed high activity of MMPs (See Figure 44, A1).  Histological studies further 
corroborated quantitative data for calcification and elastin damage 30-day post-surgery 
(See Figure 44, A2, A3).  
 
NP Targeting to Diseased Aorta 
 
Elastin antibody conjugated and DiR dye loaded NPs were injected in tail vein at 
30 days’ post-surgery.  The NPs targeted the injured aortic elastic lamina sites within the 










per weight basis) (See Figure 45A).  The fluorescence signal of DIR (% florescence/dry 
weight of organ) after 24 hours was 3.6±1.5% for the kidneys, 20±7% for the liver, and 
20±14% for the spleen (See Figure 45B).  More significantly, infiltration of the NPs was 
seen from adventitial section to the medial section which elastin is damaged (See Figure 
45C).  In a previous work we have shown, once NPs get there, they stay up to 14 days at 
the site of injury.  Based on this information we chose to inject drug loaded NPs every 
two weeks for the therapeutic studies.  
 




When blank NPs (EL-NP-Blank) or NPs loaded with an MMP inhibitor BB-94 
(EL-NP-BB94) were delivered, aortic calcification increased (67.80±16 µg and 
53.82±12.97 µg calcium/mg dry weight of aorta respectively).  When only PGG NPs 
(EL-NP-PGG) were delivered, aortic calcification did not increase, but remained similar 







Figure 45.  NP accumulation after intravenous injection of EL-NP-DIR, 30 days after 
injury at the site of elastin damage. 
 
 
EDTA NPs was followed by PGG NPs did we see significant reduction in calcification 
(16.8±4.2 µg calcium /mg dry weight of aorta) (See Figure 46). 
Alizarin Red S staining for calcification with a Light Green SF counterstain 
showed very heavy calcification in the EL-NP-Blank (See Figure 47 B1) and EL-NP-
BB94 groups (See Figure 47 B2), especially in the media and adventitia.  Calcification 

















to nonexistent in dual therapy with EL-NP-EDTA followed by EL-NP-PGG (See Figure 
47 B4).  Immunohistochemical stain for osteopontin (OPN) was positive in the EL-NP-
Blank (See Figure 47 C1) and EL-NP-BB94 (See Figure 47 C2) groups and correlated 
with high calcification.  OPN was observed, but was not abundant in the other groups 
(See Figure 47 C3 and C4). 
We used FeCl3 stain to look at PGG binding to elastin.  As expected, no phenol 
staining (black-gray for PGG) was seen in the EL-NP-Blank and EL-NP-BB94 groups 
(See Figure 47 D1 and D2).  Staining was intense in the EL-NP-EDTA+NP-PGG group 
(See Figure 47 D4) as compared to the EL-NP- PGG group (See Figure 47 D3), 
suggesting a higher amount of PGG attached to elastin after removal of mineral by 
EDTA. 
 
Aortic External Diameter Change 
 
Aortic external diameter increased from 127±20.6% to 185±25% when control 
blank NPs were injected (EL-NP-Blank), suggesting that targeted blank NPs did not 
inhibit aneurysmal growth (See Figure 48 A, B).  However, when EL-NP-PGG or EL-
NP-EDTA+EL-NP-PGG NPs were injected, a significant suppression of aortic external 
diameter change was observed (66±21% and 25±7% respectively).  Moreover, NP 











Figure 48.  Diameter change. #, P < 0.05, exact permutation test. (n=6). Wooden sticks 
were kept as reference for external diameter change measurement. 
 
 
MMP Activity and In situ Zymography 
 
We examined if delivery of NPs loaded with PGG, BB-94 or EDTA followed by 
PGG would inhibit local MMP activity at the injury site.  Fluorescence intensity data 
normalized to total protein content showed highest activity in the EL-NP-Blank group, 
clearly suggesting that blank NPs did not reduce MMP activity.  All other groups (EL-
NP-PGG, EL-NP-BB94, and EL-NP-EDTA + EL-NP-PGG) showed significant 
suppression of MMP activity (See Figure 49A).  In situ zymography confirmed the 






Figure 49.  MMP activity (-2 and -9) by fluorogenic substrate and in situ zymography. . * 
Indicates lumen. Bar = 400 μm.  (#P < 0.05, Tukey's test,) (n=6). 
 
 
Histological Analysis:  Aortic Inflammation  
 
Hematoxylin and eosin staining in EL-NP-Blank and EL-NP-BB94 groups 
showed significant adventitial inflammation with large macrophage infiltration in the 
media.  Minimal inflammation was seen in the EL-NP-EDTA+NP-PGG group (See 
Figure 50d).  Masson trichrome stain revealed that collagen deposition was abundant in 
the EL-NP-Blank (See Figure 50e) and EL-NP-BB94 (See Figure 50f) groups while 
muscle fibers were minimal.  Collagen deposition was lower in the EL-NP-PGG group 
(See Figure 50g) and minimal in EL-NP-EDTA+NP-PGG group (See Figure 50h).  
Smooth muscle staining was integrated where elastin fibers were regenerated in EL-NP-














Immunostaining for Macrophages (CD68) and Smooth Muscle Cells 
 
 EL-NP-Blank group (See Figure 51i) showed adventitial granuloma and intense 
pan-macrophage (CD-68) stain.  In EL-NP-BB94 (See Figure 51j) and EL-NP-PGG (See 
Figure 51k) groups adventitia was positive for pan-macrophages, but with lower staining 
than blank NPs.  The dual therapy group EL-NP-EDTA + EL-NP-PGG group had the 
least amount of CD68 staining (See Figure 51l).  Depletion of medial VSMCs was 
observed in both EL-NP-Blank (See Figure 51m) and EL-NP-BB94 (See Figure 51n) 
groups while more medial VSMCs were found in EL-NP-PGG (See Figure 51o) and EL-
NP-EDTA + EL-NP-PGG (See Figure 51p) groups.  
 
Systemic IFN- γ levels 
 
 EL-NP-Blank group had the highest amount of IFN- γ (23.7±7.6 pg/ml) in serum, 
followed by EL-NP-BB94 (11.2±4.8 pg/ml).  IFN- γ levels in dual therapy group (EL-
NP-EDTA + EL-NP-PGG) and EL-NP-PGG were below detectable levels.  
 
Restoration of Elastic Lamina 
 
We tested if drug therapy restored already degraded elastic lamina.  Lysyl oxidase 
enzyme activity and desmosine content was measured, as was VVG histological staining 





LOX analysis of abdominal aortic samples, as measured by ratio of thoracic aorta 













NP-BB94 groups, suggesting elastin crosslinking was inhibited.  However, EL-NP-PGG 
and EL-NP-EDTA + EL-NP-PGG groups showed a significant increase in LOX activity 




Desmosine content of abdominal aortic samples in EL-NP-Blank was further 
reduced from 421.9±104 to 205±56 pmole desmosine/mg dry tissue, suggesting further 
elastin degradation.  EL-NP-BB94 group had 317±177 pmole desmosine/mg dry, 
suggesting BB94 treatment also did not prevent elastin degradation (no significant 
differences between EL-NP-BB94 and EL-NP-Blank).  Desmosine content in the EL-NP-
PGG group was significantly higher than in the EL-NP-Blank group (571±113pmole 
desmosine/ mg dry tissue).  The EL-NP-EDTA + EL-NP-PGG group had the highest 
amount of desmosine among four groups (940±261pmole desmosine/mg dry tissue), 
clearly showing increased elastic lamina crosslinking.  A healthy non-injured aorta has 
1808±290.5 pmole desmosine/ mg dry tissue (See Figure 53). 
 
VVG Stain for Elastic Lamina 
 
Histological evaluation of elastic lamina further confirmed quantitative results. 
VVG staining for elastic lamina in aortic sections showed severe damage in the EL-NP-
Blank (See Figure 54C1) and EL-NP-BB94 (See Figure 54C2) groups, while the elastic 
lamina was partially damaged in the EL-NP-PGG (See Figure 54C3) group. However, 
elastic lamina had a natural wavy pattern as seen in healthy aortas in dual therapy group 






Figure 52.  LOX activity in the abdominal part (CaCl2 injured) over the thoracic aorta 






Figure 53.  Desmosine content of aorta of all four-groups+healthy aorta+ 30 days post 












 Healthy rat circumferential strain was ~13.7±1.5% (n=6).  In this study, we 
measured circumferential strain at two time points, 30 days after injury (before any 
treatment began (Week 4)) and Week 12 and after the treatments finished and before 
euthanasia (See Figure 55).  We have shown both values for each group and compared 
Week 4 with Week 12 in each group.  At 30 days, there was significant decrease in 
circular strain in abdominal aortas, suggesting stiffening of the artery due to loss of 
elastin, deposition of collagen, and aortic mineralization. EL-NP-Blank and EL-NP-BB94 
did not show any significant improvement in these values after 8 weeks, while both PGG 






Figure 55.  Circumferential strain of all four groups at week 4, after injury and before any 
treatment compared to Week 12 after treatment. (*P < 0.05, Tukey's test,) (n=6). Dashed 
line shows the circumferential strain in a healthy rat with no injury. 
 
 
improvement in circumferential strain, suggesting that elastin regeneration helps restore 
aortic biomechanics. 
 
Liver Function:  Alanine Aminotransferase (ALT) Analysis  
 
 Serum ALT, an enzyme used to assess liver function, was consistently within the 
acceptable range of 5-to-45 U/L (7.8±0.5 U/L for EL-NP-Blank, 6.4±0.1 U/L for EL-NP-
BB94, 5.2±0.6 U/L for EL-NP- PGG, and 6.7±0.5 U/L for EL-NP-EDTA + EL-NP-PGG 
rats).  No differences were observed in liver histological sections stained with 











The ultimate goal of pharmacological therapy for AAA is to promote regression 
of the disease and decrease the chance of surgery and rupture.  Animal studies have been 
performed using different medications, like statins, angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers and inhibitors of MMP218.  However, 
these pharmacological treatments were started at the onset of AAA induction, and these 
drugs reduced either inflammation or enzyme activity, but were unable to restore ECM 
milieu.  
Contrast agent targeting to AAA for enhanced imaging has been described219.  
Our group is working on targeted therapy for AAA that can halt or regress the disease 
with pharmacological agents. 
In our previous work, we have shown that an MMP inhibitor like BB-94, if 
targeted early, can halt the progression of AAA in a rat model200.  Similarly, we have 
shown that EDTA targeting can remove early mineral deposits in CaCl2 injury rat 
model172.  Both treatments were initiated near the initiation of the diseases.  However, 
pharmacological therapies cannot be preemptively used in patients as a precautionary 
measure.  Once diagnosed, patients will already have developed aneurysm.  Therefore, in 
this study, we validated the combinational use of targeted NPs carrying a chelating agent 
to remove calcification followed by delivery of PGG, a potent elastin protectant to 
reverse already developed calcified aneurysms in rats.  We included delivery of BB-94, 
an MMP inhibitor to test if merely suppressing further degradation of ECM restores 




Different degrees of calcification are present in most AAAs220.  Systemic EDTA 
therapy has been touted and used in many countries to improve vascular function, but it is 
still controversial221.  A recently concluded clinical trial (TACT) of systemic therapy for 
coronary disease showed slightly improved cardiovascular function that did not reach 
statistical significance and is therefore not FDA-approved222.  Systemic EDTA therapy 
can chelate calcium in the serum and can also lead to bone loss and hypocalcemia221.  
Our approach of targeted EDTA therapy requires a 20-times-lower chelating agent that is 
encased in a nanoparticle and is specifically targeted to elastin calcification sites.  In this 
study, we aimed to test if advanced calcification (30 days after injury) can be removed by 
targeted NP-based EDTA therapy.  As expected, delivery of blank NPs did not inhibit 
calcification progression.  Importantly, BB-94 delivery, although successful in inhibiting 
MMP activity at the site of AAA, was unable to prevent further calcification of the aorta.  
These data clearly show that suppression of a degradation pathway alone is insufficient to 
regress an aneurysm or existing calcification.  When PGG NPs were delivered, we saw 
inhibition of further calcification.  PGG has an affinity for proline-rich proteins like 
collagen and elastin, allowing for the formation of hydrogen bonds223.  It has been shown 
that amino and carboxyl groups are potential nucleation site for calcification on elastin224.  
PGG has many phenolic hydroxyl groups, and they can interact with these binding sites 
and form hydrogen bonds.  In this way, nucleation sites for calcium binding may have 
been blocked, and therefore, elastin was protected from further calcification.  Phenolic 
stain confirms PGG binding to elastin.  This shows that even though PGG does not have 




and block nucleation sites on elastin.  Strikingly, when we used EDTA NPs first to 
remove mineral deposits and then applied PGG NPs in a sequential manner, we saw not 
only suppression of further mineralization, but regression of deposited mineral.  After 
EDTA treatment, we saw a higher amount of PGG bind to the elastin, which led to 
blocking calcification and degradation sites.  Others have shown that OPN is abundant in 
calcified tissue and is an important regulator of arterial mineral deposition225.  Moreover, 
it has been confirmed that the aortic tissues of aneurysmal patients have more OPN than 
non-aneurysmal patients226.  In this study, OPN levels in the tissue correlated with the 
extent of calcification:  The highest OPN occurred in the blank NP group, and the lowest 
in the dual therapy group. 
Inflammation with macrophage infiltration is an important feature of AAA227.  
Pan-macrophage presence at the site of injury was abundant in the EL-NP-Blank and EL-
NP-BB94 groups.  MMP inhibitor BB-94 was unable to reduce inflammatory conditions.  
When PGG alone was delivered (EL-NP-PGG group), we saw significant reduction in 
macrophage presence.  However, when dual EDTA therapy was followed by PGG (EL-
NP-EDTA+NP-PGG group), a complete lack of macrophage presence was seen.  It is 
known that elastin fragments (EFs) or elastin degradation products (EDPs) at the site of 
injury are chemotactic to macrophages, and this mechanism is mediated by elastin 
binding proteins228.  Thus, suppression of elastin degradation may have further led to 
suppression of macrophage activity in the area and significant suppression of MMP 
activity in PGG groups.  Another reason for suppression of macrophages in the EL-NP-




OPN is a potent chemotactic factor for macrophages229; we saw reversal of OPN 
expression after removal of mineral, and this may have also lead to suppression of 
macrophages.  CaCl2-mediated aneurysm was accompanied by depletion of the medial 
layer of smooth muscle cells, which others have reported230.  In EL-NP-blank, EL-NP-
BB94 and EL-NP-PGG groups, we found depletion of VSMCs where the elastin was 
damaged.  Higher staining for viable VSMCs was observed in dual therapy (EL-NP-
EDTA+EL-NP-PGG group), probably due to removal of mineral deposits and lowering 
of inflammatory milieu in the aorta.  Systemic inflammation was tested by looking at 
serum IFN-γ levels in rats.  IFN-γ was detected in the serum of AAA patients; 
additionally, AAA sections and tissue extracts from mice contained high levels of IFN-
γ231.  We observed a higher level of IFN-γ in serum of the EL-NP-Blank and EL-NP-
BB94 groups compared to the EL-NP-PGG and EL-NP-EDTA+NP-PGG groups.  This 
clearly suggests suppression of local inflammation led to suppression in systemic 
inflammatory markers.  
Next, we looked at the elastin content of the aorta after the targeted therapy.  We 
have shown earlier that PGG treatment of vascular smooth muscle cells from aneurysmal 
aortas in culture shows enhanced deposition of insoluble elastin fibers121.  We 
hypothesize that due to PGG’s multifunctional nature, when it binds to degraded elastin 
in the ECM, it has additional binding sites that can bind and anchor soluble tropoelastin 
precursors secreted by cells.  This in turn can lead to increased lysyl oxidase (LOX) 
enzyme synthesis by cells to crosslink the tropoelastin.  LOX is an important enzyme in 




oxidizing peptidyl lysine to aminoadipic semialdehydes232.  It has been shown that 
reduced LOX activity is involved in the pathogenesis of AAA233,234.  As expected, 
aneurysmal aorta in the blank NP group showed significantly lower LOX activity as 
compared to healthy thoracic aorta.  Delivery of BB94 did not change LOX activity, 
suggesting that expression of MMPs and LOX are independently controlled.  When PGG 
was delivered either alone or after EDTA therapy, we saw significant increases in LOX 
activity similar to previous data from in vitro cell cultures121. 
We also looked at the desmosine content of the aorta, another marker for elastin 
maturation.  It has been shown that levels of desmosine are significantly lower in 
aneurysmal specimens from human patients with AAA210,235 than in controls, suggesting 
loss of mature crosslinked elastin.  We have observed that desmosine content is lower in 
all four groups compared to healthy aortas.  In our AAA model, we also observed a 
significant loss of desmosine as compared to healthy aorta levels, suggesting elastin 
degradation at the site in blank NP and BB94-NP groups.  When PGG was delivered, we 
observed an increase in desmosine content in the aneurysmal aorta.  Moreover, in the 
dual therapy group (EL-NP- EDTA /-PGG), desmosine content was significantly higher 
than in the PGG-alone group.  This suggests that calcification can be a burden to elastin 
regeneration; when calcium was removed by EDTA delivery, elastin regeneration was 
facilitated.  Our histological evaluation of elastin lamina with VVG stain corroborated 
LOX and desmosine data, showing wavy intact elastic lamina in the dual therapy group 




We next looked at whether elastin regeneration led to improvement in tissue 
biomechanical parameters.  It has been shown that loss of circumferential strain is the 
result of aneurysmal aortic degeneration236.  Circumferential strain decreased in the EL-
NP-Blank group, suggesting stiffening of the aorta.  There was a very small increase in 
the EL-NP-BB94 group, but this increase was not statistically significant compared to the 
EL-NP-Blank group.  Circumferential strain was increased after treatment with PGG 
alone and in dual therapy of EDTA and PGG (EL-NP-PGG and EL-NP-EDTA+EL-NP-
PGG groups) suggesting that the functionality of the aorta in terms of elastance can be 
restored by elastin regeneration.  Aneurysmal development as assessed by external 
diameter of aorta had progressed unhindered in blank NP and BB94-NP groups.  Delivery 
of PGG led to aneurysmal regression compared to the EL-NP-Blank and EL-NP-BB94 
groups.  The EL-NP-EDTA+EL-NP-PGG group completely reversed aneurysmal 
dilation, and the aorta size was equivalent to the healthy aorta, suggesting that the 
combinational treatment of removing calcium by EDTA and regenerating elastin by PGG 
treatment may be the best strategy to reverse the disease.  
 A significant portion of NPs in this therapy go to kidneys, spleen, and liver 
although we observed a significant decrease in NP content in the liver and kidneys two 
weeks after injections.  Thus, we hypothesize these NPs are cleared by the 
reticuloendothelial system (RES system)237.  We looked at ALT levels in livers of treated 
rats. The ALT is the most sensitive indicator of hepatic injury238.  The ALT level was the 
same among the four groups, and livers appeared normal in histological sections, 




In conclusion, we show that targeted dual NP therapy of EDTA followed by 
delivery of PGG is an effective way to reverse moderately developed aortic aneurysms 
and elastin calcification.  It regenerates elastic lamina and restores healthy elastic lamina 
in an experimental rat model of aortic aneurysms.  Thus, such therapies could be 












Elastin is an essential protein for maintaining elasticity of tissue.  Degraded 
elastin can initiate inflammatory response.  Also, damaged elastin can be a site of calcium 
nucleation.  On the other hand, regeneration of elastin is impossible in adulthood.  
Therefore, protecting elastin from degeneration and its regeneration can be valuable in 
reversal of small aneurysms when it’s diagnosed.  We have developed nanoparticles that 
can be targeted to the aneurysm site by use of unique elastin antibody that recognizes 
only degraded elastin.  First, we show that MMP inhibition with targeted nanoparticles 
loaded with an MMP inhibitor BB-94, we could suppress local MMP activity and inhibit 
initiation of elastin degradation and aneurysms in rats.  Such MMP inhibitor therapy can 
only prevent further degradation of elastin; however, it cannot restore degraded elastin.  
Therefore, we chose PGG delivery as our option.  We show that PGG can be loaded in 
polymeric nanoparticles and can be released slowly over a period of 60 days by altering 
nanoparticle preparation methods.  When such NPs were systemically delivered, they 
accumulated at aneurysmal site are released active PGG that prevented aneurysmal 
expansion of the aorta.  In advance stage of aneurysms, there is a significant calcification 
present in the aorta.  We, therefore, tried dual therapy of EDTA (to remove mineral) 
followed by PGG (to stop degradation of elastin and regenerate lost elastin).  Such dual 
therapy reversed aortic calcification and regressed aneurysmal expansion.  This was the 




Recommendation for Future Work 
 
1. PGG is known to reduce MMPs.  In our studies, we have shown that it 
reduces the number of macrophages in vivo.  It would be interesting to 
investigate its mechanisms in macrophages suppression.  Two approaches 
can be followed for this study:  1. Whether PGG interferes with metabolic 
pathways of macropahges.  Macrophages can be isolated from aneurysmal 
tissue (human or animal) and can be characterized using flow cytometry. 
After culturing them in vitro, they can be treated by PGG or PGG NPs.  To 
study the metabolic pathway, oxidative metabolism can be measured after 
incubation with PGG or PGG NPs in different time points.  2.  Whether 
PGG alters signal transduction pathways239.  To understand this, one of the 
important tests that can be done is chemotaxis assay.  The chemotactic 
effects of the PGG conditioned media can be tested in vitro using isolated 
macrophages as mentioned earlier. 
 
2. In this dissertation research, we have tried two injections of PGG 
nanoparticle because of lower targeting after two weeks compared to one 
week after injection.  It’s worth trying one injection of PGG nanoparticles to 
see if that can give the same result that two injections do as single shot 
treatment is preferred. 
 
3. In this dissertation research, we used the Calcium chloride model of 
aneurysm.  There are no animal models that faithfully recapitulate all 
features of human AAA.  It would be useful to show that this technology is 
valid and useful in other animal models like the angiotensin II-induced 
abdominal aortic aneurysm in LDL receptor knockout mice or elastase 
infusion of abdominal aorta in rats.  Calcium chloride model shows 
calcification, adventitial inflammation, and medial elastin damage but 
doesn’t show any internal diameter change.  Elastase perfusion has all the 
features of human AAA except calcification; however, it creates artificial 
faster degradation of elastin in the media causing rapid aneurysms.  Ang II 
model is only systemic treatment model that creates AAA.  It seems to show 
all aspects of human AAA although it is not specified to a region of interest 
like abdominal or thoracic aorta and AAA develop sporadically in 50% of 
animals.  None of these three animal models led to aortic rupture as seen in 
humans.  There is just one animal model that leads to aortic rupture.  By the 
time they are 5 weeks old, broad-breasted white male turkeys have 
spontaneously developed AAA. The majority of these turkeys will die due 
to aneurysms that dissect the aorta when they are fed B-aminopropionitrile 
(BAPN). This can be a very useful model because of the size of aorta and 
also because it is a naturally occurring disease240.  The only limitation is to 
get anti-turkey antibodies. Such antibodies can be generated in house.  




induced aortic dissection in rats241 which can be very easy if successful, 
because there is no surgery involved and aneurysm can be developed using 
diet.  The only drawback is that; aneurysm won’t be localized to the 
abdominal aorta. 
 
4. Elastin gene in quiescent in adults, therefore finding new stimuli can be a 
very helpful clue to rectify the pathogenesis of diseases associated with 
elastin gene dysfunction.  Thus, an interesting and essential experiment will 
be to investigate the effect of PGG on elastin gene in vitro and in vivo. 
 
5. The contractile smooth muscle cells could switch to the synthetic phenotype 
in response to pathological stimuli like thoracic aortic aneurysms242.  An in 
vitro experiment studying the effect of PGG on smooth muscle cells would 
be very interesting to see whether or not aneurysmal smooth muscle cells 
change phenotype from contractile to synthetic in presence of PGG.  It can 
be done by isolating smooth muscle cells from aneurysmal tissue (human or 
animal).  After culturing the cells, if their contractile phenotype (muscle 
(SM) α-actin (ACTA2), and SM22α (TAGLN) ) is confirmed, PGG 
treatment can be started and phenotype changes can be studies using 
immunofluorescence at different time points. 
 
6. It has been shown that AAAs varies from relatively non-inflammatory to 
inflammatory243.  In this dissertation, we looked at CD163 and CD68 
expression, but it has been shown that there are many other macrophages, T-
lymphocytes and B-lymphocytes244 present at the site of the aneurysm.  It 
would be beneficial to look at those markers and investigate the 
inflammatory response more accurately when treating with PGG.  Also 
detailed study of time course of inflammation after PGG delivery is 
warranted. 
 
7. For AAAs less than 5 cm, ultrasound is the only effective way to identify 
size. Computed tomography (CT) or CT angiography (CTA) are 
recommended as the aneurysm approaches or exceeds 5 cm or rapid 
enlargement occurs, as these imagining techniques deliver an improved 
outline of the disease. Magnetic resonance imagining (MRI) and magnetic 
resonance angiography (MRA) are also acceptable alternatives for patients 
who cannot consume iodinated contrast material due to improper renal 
function. There is no foolproof way to predict rupture risk in human patients 
based merely on diameter change, although size is commonly used to 
predict rupture risk. Variability in aorta diameter (1.5cm-2.5cm), systolic 
blood pressure, growth rate, wall stress and asymmetry index between 
patients prevents a simple evaluation based on maximum AAA diameter 
from effectively evaluating all patients245.  While our data has demonstrated 




aneurysmal aorta, it is possible to establish a quantitative relationship 
between NP binding and extent of elastin degradation and the aortic rupture 
point.  This could be a platform to predict risk of rupture by imaging a 
patient with aneurysm.  Finding a relationship between elastic damage and 
nanoparticle accumulation will be a tool to predict risk of aortic rupture.  
Gold nanoparticles could be made with surface elastin antibody that 
recognizes degraded elastin only and accumulation of gold as assessed by 
CT can be used as a measure of rupture risk in humans. 
 
8. In this dissertation research, we have not looked at biomechanical properties 
of aorta, although mechanical failure of aneurysmal aortic wall causes 
rupture and from a biomechanical standpoint, AAA rupture is related to 
mechanical wall stress.  Separate groups of rats will be needed for this 
experiment.  Biomechanical studies could be carried out on abdominal aorta 
close to renal and iliac bifurcations in treated rats vs control rats.  Uniaxial 
tensile tests could be performed to measure the mechanical strength (UTS) 
and maximum extension at failure of aortic rings.  We have shown that 
EDTA-PGG combination treatment removes mineral and restores elastin in 
the media and regresses already formed aneurysms.  It will be very 
important to see whether this combination treatment actually improves 
biomechanical function of the aorta and restores it back to the healthy status. 
 
9. Approximately 6% of the population of the United States is affected by 
brain aneurysms. Every year over 30,000 people in the U.S. suffer 
aneurysmal subarachnoid hemorrhage. Brain aneurysms also tend to occur 
with aging. Considering this novel nanoparticle technology targeting to 
elastin damage in arteries, one of the most important approach that we could 
follow is to test if such NPs can target brain aneurysm. 
 
10. EL-BB-94 NPs were optimized to target degraded elastin, deliver BB-94 to 
the site of injury, and suppress MMPs with minimal dose. BB94 has been 
used already in many cancer studies246,247 but can be a problematic drug 
when administered systemically because of musculoskeletal pain and 
inflammation248.  So, it is entirely possible that BB-94 could be employed as 
a more successful therapy using the methodology of nanoparticle 
deployment described here.  Additionally, NP surfaces could be modified to 
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